

1 **A trans-ancestry genome-wide association study of unexplained**
2 **chronic ALT elevation as a proxy for nonalcoholic fatty liver disease**
3 **with histological and radiological validation.**

4 Marijana Vujkovic^{1,2,*}, Shweta Ramdas^{3,*}, Kimberly M. Lorenz^{1,3,4}, Xiuqing Guo⁵, Rebecca
5 Darlay⁶, Heather J. Cordell⁶, Jing He⁷, Yevgeniy Gindin⁸, Chuhan Chung⁸, Rob P Meyers⁸, Carolin
6 V. Schneider³, Joseph Park^{3,2}, Kyung M. Lee⁹, Marina Serper¹, Rotonya M. Carr², David E.
7 Kaplan¹, Mary E. Haas¹⁰, Matthew T. MacLean³, Walter R. Witschey¹¹, Xiang
8 Zhu^{12,13,14,15}, Catherine Tcheandjieu^{12,16}, Rachel L. Kember^{17,18}, Henry R. Kranzler^{17,18}, Anurag
9 Verma^{1,3}, Ayush Giri¹⁹, Derek M. Klarin^{20,21,22}, Yan V. Sun^{23,24}, Jie Huang²⁵, Jennifer
10 Huffman²¹, Kate Townsend Creasy³, Nicholas J. Hand³, Ching-Ti Liu²⁶, Michelle T. Long²⁷, Jie
11 Yao⁵, Matthew Budoff²⁸, Jingyi Tan⁵, Xiaohui Li⁵, Henry J. Lin⁵, Yii-Der Ida Chen⁵, Kent D.
12 Taylor⁵, Ruey-Kang Chang⁵, Ronald M. Krauss²⁹, Silvia Vilarinho³⁰, Joseph Brancale³⁰, Jonas B.
13 Nielsen³¹, Adam E. Locke³¹, Marcus B. Jones³¹, Niek Verweij³¹, Aris Baras³¹, K. Rajender
14 Reddy², Brent A. Neuschwander-Tetri³², Jeffrey B. Schwimmer³³, Arun J. Sanyal³⁴, Naga
15 Chalasani³⁵, Katherine A. Ryan³⁶, Braxton D. Mitchell³⁷, Dipender Gill³⁸, Andrew D.
16 Wells^{39,40}, Elisabetta Manduchi⁴¹, Yedidya Saiman⁴², Nadim Mahmud⁴², Donald R.
17 Miller^{43,44}, Peter D. Reaven^{45,46}, Lawrence S. Phillips^{23,47}, Sumitra Muralidhar⁴⁸, Scott L.
18 DuVall^{9,49}, Jennifer S. Lee^{12,16}, Themistocles L. Assimes^{12,16}, Saiju Pyarajan^{21,50,51}, Kelly
19 Cho^{21,50}, Todd L. Edwards^{52,53}, Scott M. Damrauer^{1,54}, Peter W. Wilson^{23,55}, J. Michael
20 Gaziano^{21,50}, Christopher J. O'Donnell^{21,50,51}, Amit V. Khera^{20,22,51}, Struan F.A.
21 Grant^{56,40}, Christopher D. Brown³, Philip S. Tsao^{12,16}, Danish Saleheen^{57,58,59}, Luca A. Lotta³¹, Lisa

22 Bastarache⁷, Quentin M. Anstee^{60,61}, Ann K. Daly⁶⁰, James B. Meigs^{22,51,62}, Jerome I. Rotter⁵, Julie
23 A. Lynch^{9,49,63}, Regeneron Genetics Center, DiscovEHR Collaboration, EPoS Consortium
24 Investigators, VA Million Veteran Program, Daniel J. Rader^{2,3,*}, Benjamin F.
25 Voight^{1,3,4,64,*}, Kyong-Mi Chang^{1,4,*}

26

27 *These authors contributed equally

28

29 Affiliations

30 ¹Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA, ²Department of
31 Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA,
32 USA, ³Department of Genetics, University of Pennsylvania Perelman School of Medicine,
33 Philadelphia, PA, USA, ⁴Department of Systems Pharmacology and Translational Therapeutics,
34 University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA, ⁵The Institute for
35 Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist
36 Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA,
37 USA, ⁶Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne,
38 UK, ⁷Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN,
39 USA, ⁸Bioinformatics and Clinical Data Science, Gilead Sciences, Inc., Foster City, CA, USA, ⁹VA
40 Salt Lake City Health Care System, Salt Lake City, UT, USA, ¹⁰Broad Institute of MIT and Harvard,
41 Cambridge, MA, USA, ¹¹Department of Radiology, University of Pennsylvania Perelman School of
42 Medicine, Philadelphia, PA, USA, ¹²VA Palo Alto Health Care System, Palo Alto, CA,
43 USA, ¹³Department of Statistics, The Pennsylvania State University, University Park, PA,
44 USA, ¹⁴Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA,
45 USA, ¹⁵Department of Statistics, Stanford University, Stanford, CA, USA, ¹⁶Department of
46 Medicine, Stanford University School of Medicine, Stanford, CA, USA, ¹⁷Mental Illness Research
47 Education and Clinical Center, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA,
48 USA, ¹⁸Department of Psychiatry, University of Pennsylvania Perelman School of Medicine,
49 Philadelphia, PA, USA, ¹⁹Department of Obstetrics and Gynecology, Vanderbilt University Medical
50 Center, Nashville, TN, USA, ²⁰Center for Genomic Medicine, Massachusetts General Hospital,
51 Boston, MA, USA, ²¹VA Boston Healthcare System, Boston, MA, USA, ²²Program in Medical and
52 Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA, ²³Atlanta VA
53 Medical Center, Decatur, GA, USA, ²⁴Department of Epidemiology, Emory University Rollins
54 School of Public Health, Atlanta, GA, USA, ²⁵Department of Global Health, School of Public
55 Health, Peking University, Beijing, China, ²⁶Department of Biostatistics, Boston University School

56 of Public Health, Boston, MA, USA, ²⁷Department of Medicine, Section of Gastroenterology,
57 Boston University School of Medicine, Boston, MA, USA, ²⁸Department of Cardiology, The
58 Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA,
59 USA, ²⁹Department of Medicine, Children's Hospital Oakland Research Institute, Oakland, CA,
60 USA, ³⁰Departments of Internal Medicine, Section of Digestive Diseases, and of Pathology, Yale
61 School of Medicine, New Haven, CT, USA, ³¹Regeneron Genetics Center, Tarrytown, NY,
62 USA, ³²Department of Internal Medicine, Saint Louis University, St. Louis, MO, USA, ³³Department
63 of Pediatrics, University of California San Diego, La Jolla, CA, USA, ³⁴Department of Internal
64 Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA,
65 USA, ³⁵Department of Medicine, Indiana University School of Medicine, Indianapolis, IN,
66 USA, ³⁶VISN 5 Capitol Health Care Network Mental Illness Research Education and Clinical
67 Center, Baltimore, MD, USA, ³⁷Program for Personalized and Genomic Medicine, Division of
68 Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School
69 of Medicine, Baltimore, MD, USA, ³⁸Department of Epidemiology and Biostatistics, School of
70 Public Health, Imperial College London, London, UK, ³⁹Department of Pathology and Laboratory
71 Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA,
72 USA, ⁴⁰Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA,
73 USA, ⁴¹Institute for Biomedical Informatics, University of Pennsylvania Perelman School of
74 Medicine, Philadelphia, PA, USA, ⁴²Department of Medicine, Division of Gastroenterology,
75 University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA, ⁴³Edith Nourse
76 Rogers Memorial VA Hospital, Bedford, MA, USA, ⁴⁴Center for Population Health, University of
77 Massachusetts, Lowell, MA, USA, ⁴⁵Phoenix VA Health Care System, Phoenix, AZ, USA, ⁴⁶College of
78 Medicine, University of Arizona, Tucson, AZ, USA, ⁴⁷Division of Endocrinology, Emory University
79 School of Medicine, Atlanta, GA, USA, ⁴⁸Office of Research and Development, Veterans Health
80 Administration, Washington, DC, USA, ⁴⁹Department of Medicine, University of Utah School of
81 Medicine, Salt Lake City, UT, USA, ⁵⁰Department of Medicine, Brigham Women's Hospital, Boston,
82 MA, USA, ⁵¹Department of Medicine, Harvard Medical School, Boston, MA, USA, ⁵²Nashville VA
83 Medical Center, Nashville, TN, USA, ⁵³Vanderbilt Genetics Institute, Vanderbilt University Medical
84 Center, Nashville, TN, USA, ⁵⁴Department of Surgery, University of Pennsylvania Perelman School
85 of Medicine, Philadelphia, PA, USA, ⁵⁵Division of Cardiology, Emory University School of
86 Medicine, Atlanta, GA, USA, ⁵⁶Department of Pediatrics, University of Pennsylvania Perelman
87 School of Medicine, Philadelphia, PA, USA, ⁵⁷Department of Medicine, Columbia University Irving
88 Medical Center, New York, NY, USA, ⁵⁸Department of Cardiology, Columbia University Irving
89 Medical Center, New York, NY, USA, ⁵⁹Center for Non-Communicable Diseases, Karachi, Sindh,
90 Pakistan, ⁶⁰Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle
91 University, Newcastle upon Tyne, UK, ⁶¹Newcastle NIHR Biomedical Research Centre, Newcastle
92 upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, ⁶²Division of General
93 Internal Medicine, Massachusetts General Hospital, Boston, MA, USA, ⁶³College of Nursing and
94 Health Sciences, University of Massachusetts, Lowell, MA, USA, ⁶⁴Institute of Translational
95 Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine,
96 Philadelphia, PA, USA

97 **Abstract**

98 Nonalcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease. Using a
99 proxy NAFLD definition of chronic alanine aminotransferase elevation (cALT) without other liver
100 diseases, we performed a trans-ancestry genome-wide association study in the Million Veteran
101 Program including 90,408 cALT cases and 128,187 controls. In the Discovery stage, seventy-
102 seven loci exceeded genome-wide significance – including 25 without prior NAFLD or ALT
103 associations – with one additional locus identified in European-American-only and two in
104 African-American-only analyses ($P < 5 \times 10^{-8}$). External replication in cohorts with NAFLD defined
105 by histology (7,397 cases, 56,785 controls) or liver fat extracted from radiologic imaging
106 ($n = 44,289$) validated 17 SNPs ($P < 6.5 \times 10^{-4}$) of which 9 were novel (*TRIB1*, *PPARG*, *MTTP*,
107 *SERPINA1*, *FTO*, *IL1RN*, *COBLL1*, *APOH*, and *IFI30*). Pleiotropy analysis showed that 61 of 77
108 trans-ancestry and all 17 validated SNPs were jointly associated with metabolic and/or
109 inflammatory traits, revealing a complex model of genetic architecture. Our approach
110 integrating cALT, histology and imaging reveals new insights into genetic liability to NAFLD.

111

112

113 Introduction

114 Chronic liver disease with progression to cirrhosis and hepatocellular carcinoma is a global
115 health issue¹. In particular, nonalcoholic fatty liver disease (NAFLD) – a hepatic phenotype
116 associated with metabolic syndrome and insulin resistance – is an increasingly common cause
117 of chronic liver disease with an estimated world prevalence of 25% among adults¹⁻⁵. In the
118 United States (US), NAFLD prevalence is projected to reach 33.5% among the adult population
119 by 2030, due in large part to rising rates of obesity and other cardiometabolic risk factors⁶.
120 NAFLD is defined by $\geq 5\%$ fat accumulation in the liver (hepatic steatosis) in the absence of other
121 known causes for liver disease, based on liver biopsy and/or non-invasive radiologic imaging^{3,4}.
122 The clinical spectrum of NAFLD ranges from bland steatosis to nonalcoholic steatohepatitis
123 (NASH) involving inflammation and hepatocellular ballooning injury with progressive fibrosis. At
124 least 20% of patients with NAFLD develop NASH with increased risk of consequent cirrhosis and
125 primary liver cancer^{5,6}. To date, there is no licensed drug approved to treat NAFLD and prevent
126 its progression, and the general therapeutic approach focuses on improving the underlying
127 metabolic disorders such as glucose control and promotion of weight loss.

128 Individual susceptibility to NAFLD involves both genetic and environmental risk factors.
129 Current estimates of NAFLD heritability range from 20% to 50%⁷ while risk factors for NAFLD
130 include obesity (in particular, abdominal adiposity), insulin resistance and several features of
131 metabolic syndrome^{2,5,6,8}. Several genetic variants that promote the full spectrum of fatty liver
132 disease have been identified in genome-wide association studies (GWAS) utilizing cohorts
133 based on liver biopsy, imaging, and/or isolated liver enzyme values⁹⁻²². The most prominent
134 variants include p.I148M in *PNPLA3* and p.E167K in *TM6SF2*, which increase NAFLD risk, and a

135 loss-of-function variant in *HSD17B13* that confers protection against NASH¹⁶. However, the
136 limited number of genetic associations in NAFLD contrasts with other cardiometabolic disorders
137 where hundreds of loci have been mapped to date, such as obesity^{23,24}, type 2 diabetes²⁵,
138 hypertension²⁶, and plasma lipids²⁷. This highlights the need for expanded discovery with larger
139 samples and greater population diversity, with further integration of functional genomics data
140 sets to potentially identify the effector genes²⁸.

141 The Million Veteran Program (MVP) is among the world's largest and most ancestrally
142 diverse biobanks²⁹. The availability of comprehensive, longitudinally collected Veterans Health
143 Administration (VA) electronic health records for US Veteran participants in the MVP also
144 makes it a promising resource for precision medicine. However, NAFLD is markedly
145 underdiagnosed clinically due to the invasive nature of the liver biopsy procedure, variable use
146 of imaging modalities and poor sensitivity of international diagnostic codes (ICD) for NAFLD^{4,30}.
147 The use of chronic elevation of serum alanine aminotransferase levels (cALT) as a proxy for
148 NAFLD was shown to improve specificity and positive predictive value in the NAFLD diagnostic
149 algorithm within the VA Corporate Data Warehouse³¹. Accordingly, we recently adapted and
150 validated a cALT phenotype as a proxy for NAFLD to facilitate case identification in MVP²¹,
151 applying a rigorous exclusion of other conditions that are known to increase liver enzymes (e.g.,
152 viral hepatitis, alcoholic liver disease, autoimmune liver disease, and known hereditary liver
153 disease). Moreover, we showed that our cALT phenotype had a sensitivity of 80%, a specificity
154 of 89%, an accuracy of 85%, a positive predictive value of 89%, and an area-under-the-curve of
155 87% compared to gold standard abdominal imaging, liver biopsy, and clinical notes in a well-
156 characterized sample of 178 patients in the VA healthcare system. In the current study, we

157 applied this cALT phenotype in MVP participants of 4 ancestral groups³², and identified 90,408
158 NAFLD cases and 128,187 controls (**Figure 1**, and **Supplementary Figure 1**).

159 Our aims are to: (i) perform a trans-ancestry genetic susceptibility analysis of the cALT
160 phenotype in MVP; (ii) replicate the lead SNPs in external NAFLD cohorts with hepatic fat
161 defined by liver histology or radiologic imaging; (iii) identify putative causal genes at the lead
162 loci by using an ensemble “variant-to-gene” mapping method that integrates results from
163 coding and functional genomic annotations, and quantitative trait loci (QTL); and (iv) describe
164 the genetic architecture at each associated locus by characterizing the profile of additional
165 phenotypic associations using data from the GWAS catalog, MVP LabWAS, and MRC IEU
166 OpenGWAS database.

167

168 **Results**

169 ***An ancestry-diverse study population with a high prevalence of cardiometabolic traits***

170 Our study consisted of 90,408 cALT cases and 128,187 controls comprising four ancestral
171 groups, namely European-Americans (EA, 75.1%), African-Americans (AA, 17.1%), Hispanic-
172 Americans (HISP, 6.9%), and Asian-Americans (ASN, 0.9%, **Supplemental Table 1**,
173 **Supplemental Figure 1**). Consistent with the US Veteran population, MVP cases and controls
174 ($n=$ 218,595) were predominantly male (92.3%) with an average age of 64 years at study
175 enrollment (**Supplemental Table 1**). The prevalence of cirrhosis and advanced fibrosis in the
176 cALT cases ranged from 4.7% to 9.1%. With the exclusion of other known causes of liver disease
177 as described previously²¹, cases were enriched for metabolic disorders (type 2 diabetes,

178 hypertension, and dyslipidemia), suggesting a link between chronic ALT elevation and metabolic
179 risk factors.

180

181 ***Identification of trans-ancestry and ancestry-specific cALT-associated loci in MVP***

182 To identify genetic loci associated with cALT, we performed a trans-ancestry genome-wide scan
183 by meta-analyzing summary statistics derived from each individual ancestry (**Methods** and
184 **Figure 1**). In this trans-ancestry scan, 77 independent sentinel SNPs met the conventional
185 genome-wide significance level ($P < 5 \times 10^{-8}$), of which 60 SNPs exceeded trans-ancestry genome-
186 wide significance ($P < 5 \times 10^{-9}$). Of the 77 SNPs, 52 were previously reported to be associated
187 with ALT, including 9 that were also associated with NAFLD (i.e., *PNPLA3*, *TM6SF2*, *HSD17B13*,
188 *PPP1R3B*, *MTARC1*, *ERLIN1*, *APOE*, *GPAM*, and *SLC30A10*; *LYPLAL1*; **Figure 2** and **Supplemental**
189 **Table 2**)^{9-12,14,16-22,33-35}. Of the 25 newly identified loci, 14 were novel (*IL1RN*, *P2RX7*, *CASP8*,
190 *MERTK*, *TRPS1*, *OGFRL1*, *HLA*, *SMARCD2*; *DDX42*, *CRIM1*, *FLT1*, *DNAJC22*, *HKDC1*, *UHRF2*,
191 *STAP2*; *MPND*), whereas 11 have been associated with gamma-glutamyl transferase (GGT)
192 and/or alkaline phosphatase (ALP) levels³⁵.

193 In the ancestry-specific analyses, 55 loci in EAs, eight loci in AAs, and three in HISPs
194 exceeded conventional genome-wide significance ($P < 5 \times 10^{-8}$, **Supplemental Tables 3-5** and
195 **Supplemental Figures 2-4**), of which 1 EA SNP and 2 AA SNPs were not captured in the trans-
196 ancestry analysis. No variants among ASN subjects achieved genome-wide significance, likely
197 due to limited sample size (**Supplemental Figure 5**). Notably, the top two SNPs in the AA-only
198 scan (with the genes *GPT* and *ABCB4* nearby each SNP, respectively) showed stronger

199 associations than observed for *PNPLA3*. These two SNPs are polymorphic among AA's but
200 nearly monomorphic in all other populations.

201 ***Replication of cALT-associated loci in liver biopsy and radiologic imaging data***

202 To validate that our cALT-associated SNPs capture genetic susceptibility to NAFLD, we
203 assembled two external NAFLD cohorts, namely: (i) a **Liver Biopsy Cohort** consisting of 7,397
204 histologically characterized NAFLD cases and 56,785 population controls from various clinical
205 studies (**Supplemental Table 6-7**), and (ii) a **Liver Imaging Cohort** consisting of 44,289
206 participants with available radiologic liver imaging data and quantitative hepatic fat (qHF)
207 measurements (**Supplemental Table 8**). For each cohort, we performed a trans-ancestry lookup
208 of the 77 lead SNPs (**Methods**). In the Liver Biopsy Cohort, there was directional concordance
209 between effect estimates of biopsy-defined NAFLD in 66 of 77 SNPs (86%), including 15 SNPs
210 with a significant association (adjusted Bonferroni nominal $P < 6.5 \times 10^{-4}$), of which 8 have not
211 been reported in genome- or exome-wide association studies previously (e.g., *TRIB1*, *MTTP*,
212 *APOH*, *IFI30*, *COBLL1*, *SERPINA1*, *IL1RN*, and *FTO*, **Supplemental Table 7**)¹². In the Liver Imaging
213 Cohort, there was directional concordance between effect estimates of qHF in 49 of 77 SNPs
214 (64%). Among these, 11 were significantly associated with qHF (adjusted Bonferroni nominal P
215 $< 6.5 \times 10^{-4}$, **Supplemental Table 8**) of which 6 were novel (e.g., *TRIB1*, *MTTP*, *APOH*, *IFI30*,
216 *COBLL1*, and *PPARG*). As observed in previous studies owing to its role in glycogen storage (and
217 associated impact on imaging)^{12,36}, the *PPP1R3B* locus was significantly associated with qHF,
218 however in the opposite direction from cALT, and not associated with biopsy-proven NAFLD.
219 Collectively, 17 of 77 SNPs were validated in external histologic and/or radiologic NAFLD, of
220 which nine were previously unreported; namely, five in both biopsy and imaging cohorts

221 (*TRIB1*, *MTTP*, *APOH*, *IFI30*, and *COBLL1*), three in biopsy cohort alone (*FTO*, *SERPINA1*, and
222 *IL1RN*) and one in imaging cohort with a nominal significance in biopsy cohort (*PPARG*)
223 (**Supplemental Table 2**). An additional 24 SNPs were nominally associated ($P < 0.05$) with
224 directional concordance with histological and/or radiologic hepatic fat.

225 We performed a SNP-specific statistical power analysis to investigate the SNP-specific
226 type I error (α) at a P-value of $= 6.5 \times 10^{-4}$ (Bonferroni) using the respective effect estimates and
227 allele frequencies (**Supplemental Table 2 and 7**). A total of 22 loci showed sufficient statistical
228 power ($> 80\%$) for replication in the liver biopsy cohort, of which 10 replicated (**Supplemental**
229 **Figure 6**). Despite sufficient power, 12 SNPs did not replicate in the liver biopsy cohort, which
230 included *GPT*, *PPP1R3B*, *OGFRL1*, *TNFSF10*, and *PANX1*. Remarkably, in the group of 55 SNPs
231 without sufficient statistical power for replication, 6 SNPs did in fact replicate (namely *PPARG*,
232 *MTTP*, *FTO*, *IL1RN*, *IFI30*, and *COBLL1*). We note that for cALT SNPs which were replicated in the
233 histological NAFLD cohort, their effect size in histological NAFLD cohort were, on average 92.4%
234 higher than cALT effect estimate (**Supplemental Figure 7 and 8**). Extrapolating to the remaining
235 49 SNPs without 80% statistical power for replication, 22 SNPs showed higher effect sizes for
236 histological NAFLD than cALT and were therefore labeled as candidate NAFLD loci
237 (**Supplemental Table 2**).

238

239 ***Genetic risk scores and histologically characterized NAFLD***

240 We next constructed genetic risk scores (GRSs) based on effect estimates from our cALT GWAS
241 SNPs in four independent liver biopsy cohorts to quantify the cumulative predictive power of
242 our 77 sentinel variants (**Supplemental Table 9A**, **Supplemental Figure 9**). A 77 SNP-based GRS

243 was predictive of NAFLD in the meta-analyzed liver biopsy cohorts (GRS-77, $P = 3.7 \times 10^{-28}$).
244 Stratification of GRS-77 into a GRS consisting of a set of 9 well-established NAFLD SNPs (GRS-9),
245 and a GRS consisting of 68 remaining SNPs (GRS-68) revealed significant independent capacity
246 to predict histologically characterized NAFLD (GRS-9, $P = 2.2 \times 10^{-11}$; GRS-68, $P = 2.4 \times 10^{-7}$), further
247 supporting the clinical relevance of our panel of SNPs derived from proxy NAFLD phenotype.
248 We further examined the SNPs in three groups based on their strength of external replication:
249 (i) replicated at Bonferroni threshold; (ii) achieving nominal significance ($P < 0.05$) with
250 directional concordance without reaching Bonferroni significance; and (iii) $P > 0.05$. As shown in
251 **Supplemental Figure 10** and **Supplementary Table 9C**, a significant capacity for NAFLD
252 prediction was noted not only for externally replicated SNPs (Beta: 0.644, $P = 2.53 \times 10^{-10}$) but
253 also the nominal SNPs set albeit with attenuated effect (Beta: 0.198, $P = 1 \times 10^{-4}$).

254

255 ***cALT heritability and genetic correlations with other phenotypes***

256 To further characterize the architecture of our cALT phenotype and its relationship with other
257 traits, we estimated heritability and genetic correlations with other traits using linkage
258 disequilibrium (LD) score regression³⁷⁻³⁹ (**Methods**). The SNP-based liability-scaled heritability
259 was estimated at 16% (95% CI: 12-19, $P < 1 \times 10^{-6}$) in EA. Genetic correlation analysis between
260 NAFLD from the EA-only scan and 774 complex traits from LD Hub (**Methods**) identified a total
261 of 116 significant associations (adjusted Bonferroni nominal $P < 6.5 \times 10^{-5}$, **Supplemental Table**
262 **10**). These encompassed 78 cardiometabolic risk factors (67.2%) including measures of obesity
263 and adiposity, type 2 diabetes, hypertension, dyslipidemia, and coronary artery disease, which
264 is consistent with reports from observational studies correlating these traits to NAFLD⁴⁰.

265 Additional genetically correlated traits represented general health conditions (11.2%),
266 educational attainment and/or socio-economic status (12.0%) and other conditions such as
267 gastro-oesophageal reflux, osteoarthritis, gout, alcohol intake, smoking, ovary removal, and
268 urinary albumin-to-creatinine ratio (9.5%).

269

270 ***Identification of conditionally independent cALT-associated variants***

271 To discover additional conditionally independent cALT signals within the 77 genomic regions,
272 we performed exact conditional analysis using stepwise regression on individual level data for
273 all single-ancestry sentinel variants (namely 51 EA, 8 AA, and 3 HISP genomic regions). We
274 detected a total of 29 conditionally independent SNPs ($P < 1 \times 10^{-5}$) flanking five known and 16
275 novel cALT loci in EA (**Supplemental Table 11**). In particular, the *GPT* locus showed the highest
276 degree of regional complexity with 4 conditionally independent SNPs, followed by *AKNA* with 3
277 conditionally independent SNPs. For one novel locus located on chromosome 12 between 121-
278 122Mb, the trans-ancestry lead variant (rs1626329) was located in *P2RX7*, whereas the lead
279 peak variant for EA mapped to *HNF1A* (rs1169292, **Supplemental Figure 11**). Both variants are
280 in strong LD with distinct coding variants (*P2RX7*: rs1718119, Ala348Thr; *HNF1A*: rs1169288,
281 Ile27Leu) and are compelling candidate genes for metabolic liver disease. In AA, we observed a
282 total of six conditionally independent variants at three genomic regions, namely three variants
283 at *GPT*, two at *AKNA* and one at the *ABCB4* locus (**Supplemental Table 11**). No conditionally
284 independent variants were identified in Hispanic Americans. Collectively, 35 additional variants
285 were identified at 22 loci across multiple ancestries by formal conditional analysis.

286

287 ***Fine mapping to define potential causal variants in 95% credible sets***

288 To leverage the increased sample size and population diversity to improve fine-mapping
289 resolution, we computed statistically derived 95% credible sets using Wakefield's approximate
290 Bayes' factors⁴¹ using the trans-ancestry, EA, AA, and HISP summary statistics (**Supplemental**
291 **Table 12-15, Methods**. Trans-ancestry fine-mapping reduced the median 95% credible set size
292 from 9 in EA (with IQR 3 - 17) to 7.5 variants (IQR 2 - 13). A total of 11 distinct cALT associations
293 (e.g. *MTARC1*, *IL1RN*, *OGFRL1*, *PPP1R3B*, *SOX7*; *RP1L1*; *C8orf74*, *TRIB1*, *ERLIN1*, *TRIM5*,
294 *OSGIN1*; *MLYCD*, *TM6SF2* and *PNPLA3*) were resolved to a single SNP in the trans-ancestry meta-
295 regression, with an 4 additional loci suggesting single SNP sets from EA (n=2) and AA (n=2)
296 ancestry-specific scans.

297

298 ***Liver-specific enrichment of cALT heritability***

299 To ascertain the tissues contributing to the disease-association underlying cALT heritability, we
300 performed tissue-specific heritability analysis using stratified LD score regression. The strongest
301 associations were observed for genomic annotations surveyed in liver, hepatocytes, adipose,
302 and immune cell types among others (e.g., liver histone H3K36me3 and H3K4me1, adipose
303 nuclei H3K27ac, spleen TCR $\gamma\delta$, eosinophils in visceral fat; $P < 0.003$, **Supplemental Table 16**).
304 Medical subject heading (MeSH)-based analysis showed enrichment mainly in hepatocytes and
305 liver (False Discovery Rate (FDR) $< 5\%$, **Supplemental Table 17**). Gene set analysis showed
306 strongest associations for liver and lipid-related traits (P -value $< 1 \times 10^{-6}$, **Supplemental Table**
307 **18**). Enrichment analyses using publicly-available epigenomic data implemented in GREGOR
308 enrichment analysis (**Methods**) showed that most significant enrichments were observed for

309 active enhancer chromatin state in liver, epigenetic modification of histone H3 in hepatocytes
310 or liver-derived HepG2 cells (e.g. H3K27Ac, H3K9ac, H3K4me1, H3K4me3; adjusted Bonferroni
311 nominal $P < 1.8 \times 10^{-5}$, **Supplemental Table 19 and 20**). These analyses additionally support the
312 hypothesis that our cALT GWAS captures multiple physiological mechanisms that contribute to
313 NAFLD heritability. Furthermore, DEPICT-based predicted gene function nominated 28 gene
314 candidates, including the known genes *PNPLA3* and *ERLIN1* (FDR <5%, **Supplemental Table 21**),
315 as well as well-known cardiometabolic disease genes such as *PPARG*.

316

317 ***Coding variants in putative causal genes driving cALT associations***

318 There were six novel trans-ancestry loci for which the lead SNP is a coding missense variant
319 (**Supplementary Table 22**), namely Thr1412Asn in *CPS1*, Glu430Gln in *GPT*, Val112Phe in *TRIM5*,
320 Ala163Thr in *DNAJC22*, Glu366Lys in *SERPINA1* and Cys325Gly in *APOH*. To identify additional
321 coding variants that may drive the association between the lead SNPs and cALT risk, we
322 investigated predicted loss of function (pLoF) and missense variants in high LD to the identified
323 cALT lead variants ($r^2 > 0.7$ in each respective 1000 Genomes super-population, **Supplemental**
324 **Table 22**). Four previously described missense variants were replicated in the current study,
325 including Thr165Ala in *MTARC1*, Ile291Val in *ERLIN1*, Glu167Lys in *TM6SF2* and Ile148Met in
326 *PNPLA3*. Among novel loci, missense variants in high LD with lead variants included the genes
327 *CCDC18*, *MERTK*, *APOL3*, *PPARG*, *MTTP*, *MLXIPL*, *ABCB4*, *GPAM*, *SH2B3*, *P2RX7*, *ANPEP*, *IFI30*
328 and *MPV17L2*. Two additional missense variants were observed in *AKNA* and *NYNRIN*, however
329 the coding variants were outside of the calculated boundaries of their respective credible sets.
330 Among the trans-ancestry coding missense variants, eleven were predicted based on two

331 methods (SIFT, PolyPhen-2) to have potentially deleterious and/or damaging effects in protein
332 function (**Supplementary Table 22**)^{42,43}. An AA-specific locus on chromosome 7 (rs115038698,
333 chr7:87024718) was in high LD to a nearby missense variant Ala934Thr in *ABCB4* (rs61730509,
334 AFR $r^2=0.92$) with a predicted deleterious effect, where the T-allele confers an increased risk of
335 cALT ($\beta=0.617$, $P=1.8 \times 10^{-20}$). In summary, among our 77 trans-ancestry loci, 24 prioritized a
336 candidate gene based on a missense variant in high LD with the lead SNP, including 5 novel loci
337 with external validation (e.g., *SERPINA1*, *APOH*, *PPARG*, *MTTP* and *IFI30;MPV17L2*).

338

339 ***Additional approaches to nominating putative causal genes***

340 *Co-localization analyses:* We performed colocalization analyses with gene expression and
341 splicing across 48 tissues measured by the GTEx project, and overlapped our lead SNPs with
342 histone quantitative trait locus (QTL) data from primary liver to identify cALT-associated
343 variants that are also associated with change in gene expression (eQTLs), splice isoforms
344 (sQTLs), or histone modifications (hQTLs, **Methods, Supplemental Table 23**). Across all tissues,
345 a total of 123 genes were prioritized, including 20 genes expressed in liver tissue (**Methods**).
346 For liver tissue alone, a total of eight variant-gene pairs were identified where the allele
347 associated with protection against cALT was also associated with reduced transcription levels.
348 Furthermore, sQTL analysis in GTEx v8 identified two genes in the liver (*HSD17B13* and *ANPEP*)
349 and 13 genes that were affected in at least two tissues (**Supplemental Table 24**). Finally, two of
350 our lead SNPs were in high LD ($r^2 > 0.8$) with variants that regulated H3K27ac levels in liver
351 tissue (hQTLs), namely *EFHD1* (hQTL SNPs rs2140773, rs7604422 in *EFHD1*) and *FADS2* loci
352 (hQTL rs174566 in *FADS2*)⁴⁴.

353 Assay for chromatin accessibility using liver-derived cells: We next mapped our cALT loci to
354 regions of open chromatin using ATAC-seq in three biologically-relevant liver-derived tissues
355 (human liver, liver cancer cell line [HepG2], and hepatocyte-like cells [HLC] derived from
356 pluripotent stem cells)⁴⁵. Additionally, we used promoter-focused Capture-C data to identify
357 those credible sets that physically interact with genes in two relevant cell types (HepG2 and
358 liver). For each credible set, we identified genes with significant interactions (CHiCAGO score >
359 5, **Methods**) that overlap with at least one lead variant (**Supplemental Table 25**). These
360 datasets are useful entry points for deciphering regulatory mechanisms involved in the
361 pathophysiology of NAFLD. Based on DEPICT gene prediction, coding variant linkage analysis,
362 and QTL colocalization (**Supplemental Tables 18-25**), 215 potentially relevant genes were
363 identified for the 77 loci. A protein-protein interaction (PPI) analysis revealed that among the
364 192 available proteins, 86 nodes were observed, with strong PPI enrichment ($P < 9.0 \times 10^{-8}$)
365 indicating that the protein network shows substantially more interactions than expected by
366 chance (**Supplemental Table 26 and Supplemental Figure 12**).

367

368 **Variation-to-Gene Ensemble Mapping Approach to nominate putative causal genes**

369 We developed an ensemble method for predicting the likely causal effector gene at 77 loci
370 based on 8 distinct gene-mapping analyses, including: SNP-gene overlap, DEPICT gene
371 prediction, coding variant linkage, colocalization with eQTL, sQTL and hQTL, promoter Capture-
372 C and/or ATAC-Seq peak overlap, and PPI network analysis. For each gene that resides in a
373 sentinel locus, the number of times that it was identified in the eight analyses was summarized
374 into a nomination score which reflects the cumulative evidence that the respective gene is the

375 causal effector gene in the region. This ensemble method for mapping variants to genes
376 resulted in the nomination of a single gene as the causal effector gene at 53 of 77 genomic loci.
377 At the remaining 24 loci, two loci lacked any data to support the nomination of a causal gene,
378 and at 22 loci two or more causal genes were nominated because they shared the maximum
379 nomination score (**Supplemental Table 27**). We highlighted 35 loci for which a causal gene was
380 prioritized by at least 3 sources of evidence (or 4 sources of evidence for coding variants) in
381 **Table 1a/b**. These included 6 loci with co-localizing eQTLs in liver or adipose tissues and
382 connection to the predicted gene via Promoter CaptureC data (i.e., *EPHA2*, *IL1RN*, *SHROOM3*,
383 *HKDC1*, *PANX1*, *DHODH*;HP).

384 Gene expression of nominated genes in the Liver Single Cell Atlas: To confirm that the
385 nominated genes are involved in liver biology, we performed a gene expression lookup in single
386 cell RNA-Seq data from the Liver Single Cell Atlas⁴⁶. As a result, for 76 of 77 loci a gene was
387 nominated that was expressed in at least one liver cell type, with exception of the rs9668670
388 locus which nominated several keratin genes (*KRT84*; *KRT82*; *KRT74*) (**Supplemental Table 27**).

389

390 **Transcription factor analysis**

391 We observed that 14 nominated genes are transcription factors (TF) (**Supplemental Table 28**).
392 Using the DoRothEA data in OmniPath, we identified that two of these TFs have several
393 downstream target genes that were also identified in our GWAS scan (**Methods**). Notably, the
394 CEBPA TF targets the downstream genes *PPARG*, *TRIB1*, *GPAM*, *FTO*, *IRS1*, *CRIM1*, *HP*, *TBC1D8*,
395 and *CPS1*, but also *NCEH1*, a gene in the vicinity of one of our associations that lacked a

396 nominated candidate gene. Similarly, *HNF1A*, the lead gene in the EA scan (and corresponding
397 to the trans-ancestry *P2RX7* locus) targets *SLC2A2*, *MTTP*, and *APOH*.

398

399 ***Pleiotropy and related-trait genetic architecture of lead cALT SNPs***

400 We next sought to identify additional traits that were associated with our 77 trans-ancestry
401 lead SNPs using four different approaches. First, a LabWAS of distinct clinical laboratory test
402 results⁴⁷ in MVP (**Methods**) yielded 304 significant SNP-trait associations (adjusted Bonferroni
403 nominal $P = 3.1 \times 10^{-5}$, **Supplemental Table 29, Supplemental Figure 13**). Second, a PheWAS
404 Analysis in UK Biobank data using SAIGE (**Methods**) identified various SNP-trait associations
405 that mapped to loci previously associated with liver and cardiometabolic traits, as well as
406 additional enriched association for gallstones, gout, arthritis, and hernias (adjusted Bonferroni
407 nominal $P < 4.6 \times 10^{-7}$, **Supplemental Table 30**). In particular, we examined all associations for
408 PheCode 571.5, “Other chronic nonalcoholic liver disease” which comprised 1,664 cases and
409 400,055 controls, which with a disease prevalence of 0.4% seems to be underreported. Still, of
410 the 73 variants with available data, 14 were both nominally associated and directionally
411 consistent with our scan (signed binomial test $P=3.4 \times 10^{-9}$), providing additional validation for
412 our scan (**Supplementary Table 31**). Third, a SNP lookup using the curated data in the MRC IEU
413 OpenGWAS project (**Supplemental Table 32**) identified 2,892 genome-wide significant SNP-trait
414 associations for trans-ancestry SNPs, with additional 283 SNP-trait associations for the ancestry-
415 specific lead SNPs. Finally, we performed cross-trait regional colocalization analyses of EA, AA,
416 and HISP lead loci with 36 other GWAS statistics of cardiometabolic and blood cell related traits

417 **(Methods)**. This resulted in significant regional colocalization for 64 SNP-trait pairs in EA, 32
418 SNP-trait pairs in AA, and 12 SNP trait pairs in HISP (**Supplemental Table 33**).

419 Based on the four analyses described above, we selected all SNP-trait associations
420 relevant phenotypes to NAFLD biology and classified them as liver (e.g. ALT, ALP, AST, and GGT),
421 metabolic (e.g. HDL, LDL, and total cholesterol, triglycerides, BMI, glucose, and HbA1c), or
422 inflammatory traits (e.g., C-reactive protein, white blood cell count, lymphocyte count,
423 granulocytes, neutrophils, monocyte count, basophils, eosinophils, and myeloid white cells)
424 (**Supplemental Tables 29-33 Figure 3**). Across the trans-ancestry lead variants (n=77), ancestry-
425 specific variants (n=3), and secondary proximal associations (*HNF1A*, n=1), 17 trans-ancestry
426 and one EA-specific SNPs showed association with only liver traits (**Figure 3**). In contrast, 17
427 trans-ancestry and 3 ancestry-specific loci showed associations with both liver and metabolic
428 traits whereas 4 trans-ancestry loci showed associations with both liver and inflammatory
429 traits. Finally, 39 trans-ancestry loci showed association with all three traits: liver enzymes,
430 cardiometabolic traits, and inflammation, including 15 of 17 loci that were externally validated
431 in liver biopsy and/or imaging cohorts (color-coded in red in **Figure 3**). Collectively, our findings
432 identify novel cALT-associated genetic loci with pleiotropic effects that may impact hepatic,
433 metabolic and inflammatory traits.

434

435 **Pleiotropy-stratified GRS and histological NAFLD.**

436 The foregoing analyses raised the possibility that SNPs with greater pleiotropy relative to
437 metabolic and/or inflammatory traits beyond liver-related traits may have greater contributions
438 to NAFLD. To this end, we compared the GRS between four subgroups of trans-ancestry SNPs as

439 defined in **Figure 3** Venn Diagram including: (i) 17 SNPs only associated with liver traits; (ii) 5
440 SNPs associated with liver and inflammatory traits; (iii) 17 SNPs associated with liver and
441 metabolic traits; and (iv) 38 SNPs associated with liver, cardiometabolic and inflammatory
442 traits. As shown in **Supplemental Table 9D**, all 4 subgroups showed significant capacity to
443 predict NAFLD. However, the strongest effect was observed for the group combining all three
444 traits (Beta = 0.592, $P=2.8 \times 10^{-9}$) followed by liver and metabolic traits (Beta = 0.148, $P=4.6 \times$
445 10^{-6}), whereas liver trait alone and liver with inflammatory traits showed significant but
446 reduced effects (**Supplementary Figure 14**). Collectively, these findings show greater NAFLD
447 associations for pleiotropic SNPs that combine liver, metabolic and inflammatory traits.

448

449 **Directional Pleiotropy and Associated Gene Clusters.**

450 Finally, we visualized the direction and strength of the associations between the 77 trans-
451 ancestry loci and 7 inflammatory biomarkers and 13 cardiometabolic traits in a heatmap (**Figure**
452 **4**). The loci were grouped into 7 broad gene clusters using stratified agglomerative hierarchical
453 clustering (**Methods**). Gene cluster 1 consisted of 5 trans-ethnic loci (including *APOE*), for which
454 cALT risk alleles were associated with increased LDL and total cholesterol, apolipoprotein B1,
455 and markers of inflammation. Gene cluster 2 comprised of genes (such as *IL1RN*, *MTARC1*,
456 *GPAM*, and *TRIB1*) for which the cALT risk alleles were associated with increased LDL and total
457 cholesterol, apolipoprotein B1, but decreased levels of inflammatory markers. The majority of
458 the SNPs in cluster 1 and 2 were additionally characterized by lower triglyceride levels, but not
459 all. Gene cluster 3 (including *MTTP*) included genes that showed predominantly positive
460 associations with apolipoprotein B1, LDL and total cholesterol. Gene cluster 4 was characterized

461 by a lack of distinctive biomarker co-association profiles. The genes in cluster 5 (including
462 *PNPLA3*, *ERLIN1*, and *PPP1R3B*) were characterized by higher rates of type 2 diabetes, but
463 decreased levels of triglycerides, LDL cholesterol, HDL cholesterol, apolipoprotein B1,
464 apolipoprotein A1, white blood cell count, and neutrophils. The genes in cluster 6 (e.g., *PPARG*,
465 and *SLC30A10*) were associated with higher triglycerides and type 2 diabetes, but decreased sex
466 hormone binding globulin (SHBG), HDL cholesterol, and apolipoprotein 1A. Finally, the 3 genes
467 in cluster 7 (including *TM6SF2* and *FTO*) were associated with increased inflammatory markers,
468 but lower apolipoprotein B1, total and LDL cholesterol. Interestingly, for a total of 9 SNPs
469 (*TRIB1*, *PPARG*, *SLC30A10* [former *LYPLAL1*], *MLXIP*, *CEBPA*, *COBLL1*, *C6orf223*, *MIR5702*, and
470 *SH2B3*) the cALT risk allele was associated with lower BMI, consistent with a “lean NAFLD”
471 phenotype. Similarly, the cALT risk alleles of *SERPINA1* and *OSGIN1* loci seemed to be
472 associated with lower rates of type 2 diabetes, and *SH2B3* and *SLC2A2* with lower glucose and
473 HbA1c. Overall, these directional associations define distinct characteristics for each loci and
474 clusters with potential biological implications.

475

476 **Discussion**

477 In this study, we describe the first of its kind multi-ancestry GWAS of cALT as a proxy for NAFLD,
478 which resulted in a total of 77 trans-ancestry loci, of which 25 have not been associated with
479 NAFLD or ALT before. We additionally identified three ancestry-specific loci, as well as 29
480 conditionally independent SNPs in EAs and six in AAs. We assembled two external replication
481 cohorts with histologically confirmed NAFLD (7,397 NAFLD cases and 56,785 population
482 controls) and hepatic fat defined by imaging (n = 44,289), and validated the association of 17

483 SNPs with NAFLD, of which nine are novel (*TRIB1*, *PPARG*, *MTTP*, *SERPINA1*, *FTO*, *IL1RN*,
484 *COBLL1*, *APOH*, and *IFI30*). Furthermore, a GRS based on novel SNPs alone was predictive of
485 histologically defined NAFLD.

486 Pleiotropy analysis allowed us to characterize the genetic architecture of NAFLD and all
487 validated SNPs showed significant associations with metabolic risk factors and/or inflammatory
488 traits, the most common being plasma lipid-related, followed by glycemic traits, hypertension,
489 and cardiovascular disease. A GRS based on the subset of SNPs that are associated with cALT,
490 cardiometabolic traits, and inflammatory markers showed the highest capacity to predict
491 histological NAFLD. Our ensemble variant-to-gene mapping method nominated a single causal
492 effector gene at 53 genomic loci. We found that these genes were highly expressed in one or
493 more cell types in the liver and have prior biological connections to liver metabolism,
494 physiology, or disease, making this list compelling for further interrogation. Our directional
495 pleiotropy analysis for metabolic risk factors are overall concordant with the results from Sliz et
496 al, which investigated 4 NAFLD SNPs (*LYPLAL1*, *PNPLA3*, *GCKR*, and *TM6SF2*).⁴⁸ In addition to
497 associations with inflammatory markers, we show that the risk alleles of *TM6SF2*, *PNPLA3*, and
498 *SLC30A10* (former *LYPLAL1*) are positively associated with type 2 diabetes and HbA1c.
499 Collectively, our findings offer a comprehensive, expanded, and refined view of the genetic
500 contribution to cALT with potential clinical, pathogenic, and therapeutic relevance.

501 Our proxy NAFLD phenotype was based on chronic ALT elevation with the exclusion of
502 other known diagnoses of liver disease or causes of ALT elevation (e.g. viral hepatitis, alcoholic
503 liver disease, hemochromatosis), based on previous validation within VA population^{21,31}. In this
504 regard, several GWAS studies of liver enzyme levels have been reported, particularly of serum

505 ALT^{10,11,16,34,35}, but not all studies systematically excluded other causes of ALT elevation. For
506 example, Pazoki *et al.* recently reported 230 loci related to ALT, of which 52 were also included
507 in our panel of 77 (67.5%) lead cALT loci^{34,35}. While our cALT approach was designed to enhance
508 the specificity of non-invasive NAFLD diagnosis^{21,31}, this overlap is not surprising given the high
509 prevalence of NAFLD in the general population. Furthermore, we noted that inflammatory traits
510 were associated with over half of the cALT loci in our study. Indeed, while ALT can be normal in
511 patients with hepatic steatosis, we focused on chronic ALT elevation that represents ongoing
512 hepatocellular injury that can promote liver disease progression. For our controls, we excluded
513 individuals with mild ALT elevation and selected healthier ‘super-controls’ to minimize potential
514 phenotype misclassification (e.g. attributing cases as controls). We recognize that some cALT
515 loci such as GPT may be involved more directly in ALT biology rather than NAFLD. Based on the
516 observation that replicated SNPs had higher effect sizes in the histological cohort than for cALT,
517 we hypothesize that 22 non-replicated SNPs with higher effect sizes for histological NAFLD than
518 cALT are candidate loci for NAFLD. In addition, our pleiotropy analyses suggest that 24 non-
519 replicated cALT SNPs associated with metabolic and inflammatory traits are more likely to be
520 related to NAFLD, of which 12 SNPs overlap with the list of candidate NAFLD loci.

521 The MVP is one of the world’s largest and most ancestrally diverse biobanks, of which
522 25% of the participants are of non-white ancestry, and this diversity enhanced the value of this
523 study. Utilizing data from multiple ancestries allowed us to narrow down putative causal
524 variants for NAFLD through trans-ancestry fine-mapping. Moreover, we identified two cALT
525 NAFLD loci specifically in AAs. For example, the lead SNP at the *ABCB4* locus (rs115038698) was
526 in high LD with the missense variant rs61730509 (Ala934Thr, AFR $r^2=0.92$) and had a very

527 potent effect (OR=1.87, CI=1.64-2.14, $P=1.8 \times 10^{-20}$). This variant is of low frequency in AA
528 (MAF=1.2%) but virtually absent in EA and ASN. *ABCB4*, also known as multidrug resistance
529 protein 3 (*MDR3*), is a compelling candidate gene, as it is involved in hepatocyte lipid transport
530 and has been previously implicated in cholestasis, gallbladder disease, and adult biliary
531 fibrosis/cirrhosis⁴⁹⁻⁵¹.

532 Ultimately, the affirmative external validation of our lead cALT loci in NAFLD cohorts
533 with liver biopsies and imaging supports the relevance of our proxy phenotype for NAFLD. A
534 total of 17 loci associated with cALT were also significantly associated with hepatic fat based on
535 liver biopsy and/or radiological imaging. These included loci previously associated with NAFLD
536 or all-cause cirrhosis (e.g., *PNPLA3*, *TM6SF2*, *HSD17B13*, *MTARC1*, *ERLIN1*, *GPAM*, and *APOE*),
537 but also included several of the novel loci reported here (e.g., *TRIB1*, *SERPINA1*, *MTPP*, *IL1RN*,
538 *IFI30*, *COBLL1*, *APOH*, *FTO*, *PPP1R3B* and *PPARG*). For all loci except *PPP1R3B*, we observed
539 concordant directionality of effects between cALT and hepatic fat. The apparent discrepancy in
540 the *PPP1R3B* locus has been reported before¹² and may represent diffuse attenuation on
541 radiologic images due to hepatic accumulation of glycogen^{36,52} rather than triglycerides⁵³. These
542 novel and validated genes make excellent gene candidates for NAFLD. In addition, our study
543 failed to replicate the *GCKR* locus, where a common missense variant (rs780094) has been
544 repeatedly shown to confer susceptibility to NAFLD²⁰. The SNP is a risk factor for increased
545 triglycerides, C-reactive protein, LDL cholesterol, but seems to be protective for T2D, fasting
546 glucose, alcohol intake, AUD, BMI, and monocyte percentage. It is hypothesized that the
547 variant *GCKR* protein loses interaction efficiency with glucokinase, which promotes hepatic
548 glucose metabolism, decreases plasma glucose levels, and increases NAFLD risk⁵⁴. Our

549 phenotype might not be a suitable proxy for NAFLD for SNPs that act through multiple
550 pathways with opposing effects on ALT.

551 A substantial fraction of our cALT loci showed a shared genetic co-architecture with
552 metabolic traits (**Figure 4**). Of interest is that for 9 SNPs the cALT risk allele was associated with
553 lower BMI, including *PPARG*. These SNPs seem to exhibit mild lipodystrophic effects,
554 characterized by reduced adipose tissue and increased hepatic steatosis. Further study is
555 required to clarify whether and which loci are working primarily in adipose tissue with a
556 secondary effect on liver steatosis.

557 Several genes and liver-enriched transcription factors involved in LDL and triglyceride
558 pathways have been indentified, such as the liver-biopsy and/or imaging validated *TRIB1*,
559 *FTO*^{55,56}, *COBLL1*^{57,58}, *MTTP*, *TM6SF2*, *PPARG*, *APOE*, and *GPAM*⁵⁹⁻⁶², but also the cALT-only
560 associated variants in *MLXIPL*, *MLXIP*, *CEBPA*, *FADS2*, *APOH*, *RORA*, and *HNF1A*. *TRIB1*
561 presumably regulates VLDL secretion by promoting the degradation carbohydrate-response
562 element binding protein (ChREBP, encoded by *MLXIPL*), reducing hepatic lipogenesis and
563 limiting triglyceride availability for apolipoprotein B (apoB) lipidation. Furthermore, *TRIB1* co-
564 activates the transcription of *MTTP*, which encodes the microsomal triglyceride transfer protein
565 that loads lipids onto assembling VLDL particles and facilitates their secretion by hepatocytes.
566 Lomitapide, a small molecule inhibitor of *MTTP*, is approved as a treatment for lowering LDL
567 cholesterol in homozygous familial hypercholesterolemia⁶³ and a potential therapeutic target
568 for NAFLD. *TRIB1* is also involved in the degradation of the key hepatocyte transcription factor,
569 CCAAT/enhancer-binding protein alpha (*CEBPA*)⁶⁴, which together with *HNF1A* (HNF1
570 Homeobox A), *RORα* (retinoic acid receptor-related orphan receptor-α) and *MIR-122* are

571 involved in a feedback loop of the the liver-enriched transcription factor network to control
572 hepatocyte differentiation⁶⁵. ROR α is also a suppressor of transcriptional activity of peroxisome
573 proliferator-activated receptor γ (PPAR γ)^{66,67}. *PPARG*, encoding PPAR γ , upregulates LDL-
574 receptor-related protein 1 (*LRP1*), which facilitates the hepatic uptake of triglyceride-rich
575 lipoproteins via interaction with apolipoprotein E (apoE)^{68,69}. *PPARG* is predominantly
576 expressed in adipose tissue, and hepatic expression levels of *PPARG* are significantly increased
577 in patients with NAFLD⁷⁰. Large randomized controlled clinical trials have reported that the
578 *PPARG* agonists rosiglitazone and pioglitazone improve NAFLD-related hepatic steatosis,
579 hepatic inflammation, and fibrosis⁷¹⁻⁷⁵. However, the treatment is frequently accompanied with
580 weight gain and fluid retention, limiting its application and potential long-term drug adherence.
581 ROR α however, competes with PPAR γ for binding to PPAR γ target promoters, and therapeutic
582 strategies designed to modulate ROR α activity in conjunction with PPAR γ may be beneficial for
583 the treatment of NAFLD. ApoE and ApoH⁵⁹ play an important role in the production and
584 clearance of VLDL by facilitating the hepatic uptake of triglyceride-rich lipoproteins⁷⁶⁻⁷⁹. ApoE
585 deficiency is suggested to affect hepatic lipid deposition in dietary-challenged murine models⁸⁰.
586 Similarly, a Western high-fat cholesterol-rich diet accelerates the formation of NASH with
587 fibrosis in ApoE-deficient mice⁸¹.

588 More than half of our cALT loci had a significant association with at least one
589 inflammatory trait (**Figure 4**), consistent with the multiple-hit hypothesis of NAFLD⁸². For
590 example, the transcription factor MafB regulates macrophage differentiation⁸³ and genetic
591 variation in *MAFB* has been associated with hyperlipidemia and hypercholesterolemia²⁷. Mice
592 with macrophage-specific *Mafb*-deficiency are more susceptible to obesity and

593 atherosclerosis^{84,85}. *FADS1* and *FADS2* are markedly induced during monocyte to macrophage
594 differentiation, and it is hypothesized that they impact metabolic disease by balancing
595 proinflammatory and proresolving lipid mediators^{86,87}. Another interesting locus is *IL1RN*, which
596 in our study is associated with lower risk of cALT and liver-biopsy characterized NAFLD. GTEx
597 data shows heterogeneous directions of effect across various tissues, with the minor G-allele
598 being associated with increased *IL1RN* expression in liver but decreased expression in
599 subcutaneous adipose tissue. *IL1RN* encodes the anti-inflammatory cytokine interleukin-1
600 receptor antagonist (IL-1Ra) and is a natural inhibitor of IL-1 activity by blocking the binding of
601 IL-1 β to IL-1R, and is considered a potential therapeutic target for NAFLD treatment⁸⁸. IL-1 β has
602 been shown to lead to chronic low-grade inflammation⁸⁹⁻⁹¹, insulin resistance and hepatic fat,
603 and promotes hepatic steatosis, inflammation and fibrosis^{92,93}. A study in mice has shown that
604 IL-1R-deficiency protects from liver fibrosis⁹⁴, and the deletion of IL-1R reduces liver injury in
605 acute liver disease by blocking IL-1 driven autoinflammation⁹⁵. In two studies of patients with
606 diabetes, blockade of IL-1 signaling with Anakinra (a recombinant form of IL-1Ra) improved
607 glycemic control⁹⁶⁻⁹⁸. It remains to be investigated whether remodeling of the adipose tissue
608 inflammasome via IL-1 signaling blockade in obesity-associated NAFLD offers potential
609 therapeutic benefit. Other loci implicated with inflammatory traits include *RORA*^{99,100},
610 *IFI30*^{101,102}, *CD276*¹⁰³⁻¹⁰⁵, *FCGR2A*¹⁰⁶, and *P2RX7*¹⁰⁷⁻¹⁰⁹. Interestingly, these inflammation-related
611 genes and pathways emerged from our cALT GWAS despite the indirect assessment of our
612 phenotype, clearly implicating inflammation early in NAFLD.

613 Finally, *PANX1* and *MERTK* genes that are associated with liver traits only seem
614 particularly interesting. For *PANX1*, the directional concordance of effects between cALT and

615 *PANX1* gene expression in the liver suggests possible relevance as a therapeutic target. It has
616 been reported that the genetic deletion of Pannexin 1 (encoded by *PANX1*) has a protective
617 effect in a mouse model of acute and chronic liver disease^{110,111}, and our data demonstrate that
618 a SNP near *PANX1* was associated with reduced *PANX1* expression and reduced risk of NAFLD.
619 These data nominate *PANX1* as a therapeutic target for silencing in NAFLD treatment. For
620 MerTK, two missense variants (Arg466Lys and Ile518Val, $r^2=0.98$) were predicted to affect
621 protein function. MerTK signaling in hepatic macrophages was recently shown to mediate
622 hepatic stellate cell activation and promote hepatic fibrosis progression¹¹². Variants in *MERTK*
623 were associated with liver fibrosis progression in HCV-infected patients¹¹³, raising the possibility
624 for MerTK as a novel therapeutic target against fibrosis¹¹⁴. We emphasize that functional
625 studies of our nominated causal genes are needed to demonstrate casual relevance, their
626 impact on hepatosteatosis, and ultimately to determine their underlying mechanisms.

627 In conclusion, we discovered 77 genomic loci associated with cALT in a large, ancestrally
628 diverse cohort. Our cases of cALT were excluded for other known causes of liver disease or
629 elevated ALT and, not surprisingly, were substantially enriched for metabolic disorders. We
630 replicated our findings in external cohorts with hepatic fat defined by liver biopsy or radiologic
631 imaging. The genetic architecture of the lead loci indicate a predominant involvement of
632 metabolic and inflammatory pathways. This study constitutes a much-needed large-scale,
633 multi-ancestry genetic resource that can be used to build genetic prediction models, identify
634 causal mechanisms, and understand biological pathways contributing to NAFLD initiation and
635 disease progression.

636

637 **Table 1a. Gene nominations at loci with strongest evidence for coding variants.**

SNP	Position	Gene	AA-Change	SIFT/PP2*	e/sQTL**	Other†	Pleiotropy‡
rs6541349	1:93787867	CCDC18	p.Leu1134Val	+/-	+	.	M
rs2642438	1:220970028	MTARC1	p.Thr165Ala	-/-	+(A)	+	M
rs11683409	2:112770134	MERTK	p.Arg466Lys	-/-	.	++	.
rs17036160	3:12329783	PPARG	p.Pro12Ala	-/-	+	++	M
rs17598226	4:100496891	MTTP	p.Ile128Thr	-/-	+	+	.
rs115038698	7:87024718	ABCB4	p.Ala934Thr	+/+	+	+	M,I
rs799165	7:73052057	MLXIPL	p.Gln241His	-/+	+	+	M,I
			p.Ala358Val	-/-	+	+	M,I
rs7041363	9:117146043	AKNA	p.Pro624Leu	+/-	+	+	M
rs10883451	10:101924418	ERLIN1	p.Ile291Val	-/-	.	++	M
rs4918722	10:113947040	GPAM	p.Ile43Val	-/-	+	++	M
rs11601507	11:5701074	TRIM5	p.Val112Phe	-/-	.	++	M,I
rs1626329	12:121622023	P2RX7	p.Ala348Thr	-/-	+	+	.
rs11621792	14:24871926	NYNRIN	p.Ala978Thr	-/-	+(L,A)	+	M,I
rs28929474	14:94844947	SERPINA1	p.Glu366Lys	-/+	.	+++	M,I
rs7168849	15:90346227	ANPEP	p.Ala311Val	-/-	+(L)	+	.
rs1801689	17:64210580	APOH	p.Cys325Gly	+/+	.	++	M,I
rs132665	22:36564170	APOL3	p.Ser39Arg	-/-	+(A)	+	.
rs738408	22:44324730	PNPLA3	p.Ile148Met	+/+	.	+++	M,I

638 Genes nominated with various sources of evidence are listed as follows.

639 *Prio to the slash symbol: '+' indicates 'deleterious' in SIFT and '-' otherwise. After slash symbol: '+'
 640 denotes probably damaging in Polyphen-2 and '-' otherwise.

641 ** The '+' indicates colocalization between NAFLD GWAS variant and GTEx QTL varint (COLOC
 642 PP4/(PP3+PP4) > 0.9). (L) denotes QTL effect in Liver, (A) denotes QTL in Adipose.

643 †Each '+' represent evidence from DEPICT, PPI data, or if the lead SNP is within the transcript; coding
 644 variants also include '+' from hQTLs/Capture-C evidence.

645 ‡Pleiotropy is limited to association with Metabolic (M) or Inflammatory (I) Traits

646

647

648 **Table 1b. Gene nominations at loci with strongest evidence for non-coding variants.**

SNP	Position	Gene	hQTL	CaptureC	e/sQTL**	Other [†]	Pleiotropy [‡]
rs36086195	1:16510894	EPHA2	.	+	+(L,A)	+	M
rs6734238	2:113841030	IL1RN	.	+	+(A)	++	I
rs10201587	2:202202791	CASP8	.	+	+	+	M
rs11683367	2:233510011	EFHD1	+	.	+(L)	+	.
rs61791108	3:170732742	SLC2A2	.	+	.	+++	M
rs7653249	3:136005792	PCCB	.	.	+	++	M,I
rs12500824	4:77416627	SHROOM3	.	+	+(L)	+	M
rs10433937	4:88230100	HSD17B13	.	.	+(L,A)	+	M,I
rs799165	7:73052057	BCL7B	.	+	+	+	M,I
rs687621	9:136137065	ABO	.	.	+	+	M,I
rs35199395	10:70983936	HKDC1	.	+	+(L,A)	+	M
rs174535	11:61551356	FADS2	+	.	+(A)	++	M,I
rs56175344	11:93864393	PANX1	.	.	+(L,A)	++	.
rs34123446	12:122511238	MLXIP	.	+	+	+	M,I
rs12149380	16:72043546	DHODH	.	+	+	+	M,I
		HP	.	+	+(A)	.	M,I
rs2727324	17:61922102	DDX42	.	+	+	+	M
		SMARCD2	.	.	+	+	M
rs5117	19:45418790	APOC1	.	.	+	++	M,I

649 Genes nominated with various sources of evidence are listed as follows.

650 *Prio to the slash symbol: '+' indicates 'deleterious' in SIFT and '-' otherwise. After slash symbol: '+'
 651 denotes probably damaging in Polyphen-2 and '-' otherwise.

652 ** The '+' indicates colocalization between NAFLD GWAS variant and GTEx QTL varint (COLOC
 653 PP4/(PP3+PP4) > 0.9). (L) denotes QTL effect in Liver, (A) denotes QTL in Adipose.


654 †Each '+' represent evidence from DEPICT, PPI data, or if the lead SNP is within the transcript; coding
 655 variants also include '+' from hQTLs/Capture-C evidence.

656 ‡Pleiotropy is limited to association with Metabolic (M) or Inflammatory (I) Traits

657

658


659 **Figure 1. Overview of analysis pipeline.**



660


661 The flow diagram shows in the red box our study design with initial inclusion of 430,400 Million Veteran Program
662 participants with genotyping and ancestry classification by HARE, exclusion of individuals with known liver disease
663 or alcohol dependence and inclusion of subjects based on chronic ALT elevation (case) or normal ALT (control).
664 This resulted in 90,408 NAFLD cases and 128,187 controls with EA, AA, HISP and ASN ancestries that were
665 examined in primary trans-ancestry and ancestry-specific genome-wide association scans. The orange box of the
666 flow diagram highlights our results of trans-ancestry and ancestry-specific meta-analyses identifying 77 trans-
667 ancestry loci + 1 EA-specific + 2 AA-specific loci that met genome-wide significance. The green box summarizes the
668 results from external replication cohorts, whereas the blue box indicates all the post-GWAS annotation analyses
669 that we performed, which include secondary signal analysis, fine-mapping (95% credible sets), (tissue-specific)
670 heritability estimation, genetic correlations analysis, variant-to-gene mapping and pleiotropy analysis.
671

672 Figure 2. Manhattan plot of NAFLD GWAS of 90,408 NAFLD and 128, 187 controls in trans-
673 ancestry meta-analysis.




674
675 Nominated genes are indicated for 77 loci reaching genome-wide significance ($P < 5 \times 10^{-8}$). Previously reported
676 NAFLD-loci with genome-wide significant association are indicated in green font. The red stars indicate the SNPs
677 that have been validated with liver biopsy and/or radiologic imaging.

679 **Figure 3. Venn diagram depicting overlapping liver, metabolic and inflammatory traits among**
 680 **NAFLD-associated loci.**



681
 682 Overlapping liver (black), metabolic (purple) and/or inflammatory (green) traits are shown in
 683 association with 77 trans-ancestry and additional ancestry-specific lead SNPs. The trait categorizations reflect
 684 significant SNP-trait associations identified by: 1) LabWAS of clinical laboratory results in MVP; 2) PheWAS with
 685 UKBB data using SAIGE; 3) SNP lookup using the curated data in the IEU OpenGWAS projects; and 4) cross-trait
 686 colocalization analyses using COLOC of EA, AA and HISP lead loci with 36 other GWAS statistics of cardiometabolic
 687 and blood cell related traits. Genes denoted in bold and color-coded in red refer to the loci also associated
 688 with quantitative hepatic fat on imaging analyses or histologically characterized NAFLD from liver biopsies. * Locus
 689 identified in European-only GWAS. ** Locus identified in African American-restricted analysis. *Secondary signal
 690 from European analysis (e.g. HNF1A/P2RX7).
 691

692 **Figure 4: Seven gene clusters with distinct biomarker association profiles.**



693
 694 The 77 loci cluster along 7 groups using stratified linkage hierarchical clustering. Each cluster has a distinct
 695 biomarker association profile, which is visualized with a heatmap. Twenty traits are clustered within their
 696 biological strata (e.g. lipids, inflammation, and metabolic). The color coding corresponds to the direction of

697 association of the cALT risk allele (red, positive association; blue, negative association) and the strength of the
698 association based on the P-value.

699 **Methods**

700 We performed a large-scale trans-ancestry NAFLD GWAS in the Million Veteran Program. We
701 subsequently conducted analyses to facilitate the prioritization of these individual findings,
702 including transcriptome-wide predicted gene expression, secondary signal analysis, coding
703 variant mapping, variant-to-gene mapping, and pleiotropy analysis to fine-map the genomic loci
704 to putatively causal genes and biological mechanisms.

705

706 *Discovery cohort in Million Veteran Program.*

707 The Million Veteran Program (MVP) is a mega-biobank that was launched in 2011 and
708 supported entirely by the Veterans Health Administration (VA) Office of Research and
709 Development in the United States (US) of America, to develop a genetic repository of US
710 Veterans with additional information through the VA electronic health record system and MVP
711 questionnaires to learn how genes, lifestyle and military exposure affect health and disease.
712 The MVP received ethical and study protocol approval from the VA Central Institutional Review
713 Board (IRB) in accordance with the principles outlined in the Declaration of Helsinki. Over 60 VA
714 Medical Centers have participated in this study nationally. The specific design, initial
715 demographics of the MVP have been detailed previously²⁹. Electronic health record information
716 from the VA's Corporate Data Warehouse (CDW) was used for clinical and demographic
717 information. For genetic analyses, DNA extracted from whole blood was genotyped in
718 customized Affymetrix Axiom Array which contains a total of 723,305 SNPs enriched for: 1) low

719 frequency variants in AA and HISP populations, and 2) variants associated with diseases
720 common to the VA population²⁹. Further quality control procedures have been previously
721 described¹¹⁵.

722 Proxy NAFLD Phenotype: MVP NAFLD phenotype definitions were developed by combining a
723 previously published VA CDW ALT-based approach with non-invasive clinical parameters
724 available to practicing clinicians at the point of care^{21,31}. The primary NAFLD phenotype
725 (labeled “ALT-threshold”) was defined by: (i) elevated ALT >40 U/L for men or >30 U/L for
726 women during at least two time points at least 6 months apart within a two-year window
727 period at any point prior to enrollment and (ii) exclusion of other causes of liver disease (e.g.,
728 presence of chronic viral hepatitis B or C (defined as positive hepatitis C RNA > 0 international
729 units/mL or positive hepatitis B surface antigen), chronic liver diseases or systemic conditions
730 (e.g., hemochromatosis, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune
731 hepatitis, alpha-1-antitrypsin deficiency, sarcoidosis, metastatic liver cancer, secondary biliary
732 cirrhosis, Wilson’s disease), and/or alcohol use disorder (e.g., alcohol use disorder, alcoholic
733 liver disease, alcoholic hepatitis and/or ascites, alcoholic fibrosis and sclerosis of liver, alcoholic
734 cirrhosis of liver and/or ascites, alcoholic hepatic failure and/or coma, and unspecified alcoholic
735 liver disease). The control group was defined by having a: normal ALT (≤ 30 U/L for men, ≤ 20 U/L
736 for women) and no apparent causes of liver disease or alcohol use disorder or related
737 conditions²¹. Habitual alcohol consumption was assessed with the age-adjusted Alcohol Use
738 Disorders Identification Test (AUDIT-C) score, a validated questionnaire annually administered
739 by VA primary care practitioners and used previously in MVP^{116,117}. Demographics of the NAFLD
740 cohort are shown in **Supplementary Table 1**. The prevalence of cirrhosis and advanced fibrosis

741 was based on the following ICD-9 codes: 456.2, 456.21, 571.5, 572.2, 572.3 , and ICD-10 codes:

742 K72.9, K72.91, K74.0, K74.02, K74.1, K74.2, K74.6, K74.69

743

744

745 *Single-variant autosomal analyses.*

746 We tested imputed SNPs that passed quality control (i.e. $HWE > 1 \times 10^{-10}$, $INFO > 0.3$, call rate $>$
747 0.975) for association with NAFLD through logistic regression assuming an additive model of
748 variants with $MAF > 0.1\%$ in European American (EA), and $MAF > 1\%$ in African Americans (AA),
749 Hispanic Americans (HISP), and Asian Americans (ASN) using PLINK2a software¹¹⁸. Indels were
750 excluded from analysis. Covariates included age, gender, age-adjusted AUDIT-C score, and first
751 10 principal components (PC's) of genetic ancestry. We aggregated association summary
752 statistics from the ancestry-specific analyses and performed a trans-ancestry meta-analysis. The
753 association summary statistics for each analysis were meta-analyzed in a fixed-effects model
754 using METAL with inverse-variance weighting of log odds ratios¹¹⁹. Variants were clumped using
755 a range of 500kb and/or CEU $r^2 LD > 0.05$, and were considered genome-wide significant if they
756 passed the conventional p-value threshold of 5×10^{-8} . Trans-ancestry and ancestry-specific
757 summary statistics are displayed in **Supplementary Tables 2-5**.

758

759 *Secondary signal analysis.*

760 The PLINK `--condition` and `--condition-list` parameters were used to conduct stepwise
761 conditional analyses on individual level data in MVP to detect ancestry-specific distinct
762 association signals nearby lead SNPs. Regional SNPs were eligible if they were located within
763 500kb of lead SNP, had a $MAF > 1\%$ and passed standard quality control criteria ($INFO > 0.3$,
764 $HWE P > 1.0 \times 10^{-10}$, call rate > 0.975). Logistic regression was performed in a stepwise fashion,
765 starting with a regional association analysis with the following set of covariates: lead SNP
766 imputed allele dosage, age, gender, and 10 PC's of genetic ancestry. If the corresponding

767 output file contained SNP(s) that reached locus-wide significance ($P < 1.0 \times 10^{-5}$), the most
768 significant SNP was selected and added to the covariate set. The regression was repeated until
769 no locus-wide significant SNPs remained. Secondary signals are shown in **Supplementary Table**
770 **11**.

771
772 *Credible Sets.*

773 We calculated Wakefield's approximate Bayes' factors⁴¹ based on the marginal summary
774 statistics of the trans-ancestry meta-analysis and ancestry specific summary statistics using the
775 CRAN R package `corrcoverage`¹²⁰. For each locus, the posterior probabilities of each variant
776 being causal were calculated and a 95% credible set was generated which contains the
777 minimum set of variants that jointly have at least 95% posterior probability (PP) of including the
778 causal variant (**Supplementary Tables 12-15**).

779
780 *External validation in a Liver Imaging cohort.*

781 A replication lookup of lead loci was performed to evaluate the extent to which genetic
782 predictors of hepatocellular injury (cALT) correspond with quantitative hepatic fat derived from
783 computed tomography (CT) / magnetic resonance imaging (MRI)-measured hepatic fat in the
784 Penn Medicine Biobank (PMBB), UK Biobank, Multi-Ethnic Study of Atherosclerosis (MESA),
785 Framingham Heart Study (FHS), and University of Maryland Older Order Amish study
786 (**Supplementary Table 8**). Attenuation was measured in Hounsfield units. The difference
787 between the spleen and liver attenuation was measured for PMBB; a ratio between liver
788 attenuation/spleen attenuation was used for MESA and Amish; and liver attenuation/phantom

789 attenuation ratio in FHS as previously described by Speliotes *et al*¹². Abdominal MRI data from
790 UK Biobank data were used to quantify liver fat using a two-stage machine learning approach
791 with deep convolutional neural networks¹²¹. CT-measured hepatic fat was estimated using a
792 multi-stage series of neural networks for presence of scan contrast and liver segmentation
793 using convolutional neural networks. The PMBB included CT data on 2,979 EA and 1,250 AA
794 participants¹²², the FHS included a total of 3,011 EA participants, the Amish study 754 EA
795 participants, and MESA contributed 1,525 EA, 1,048 AA, 923 HISP, and 360 ASN participants for
796 concordance analysis. The UK Biobank included MRI image data from 36,703 EA participants. All
797 cohorts underwent individual-level linear regression analysis on hepatic fat, adjusted for the
798 covariates of age, gender, first 10 principal components of genetic ancestry, and alcohol intake
799 if available. If the lead SNP was not available in any of the studies, a proxy SNP in high LD with
800 the lead variant was used ($r^2 > 0.7$) or if no such variant was identified, the SNP was set to
801 missing for that respective study. The study-specific ancestry-stratified summary statistics were
802 first standardized to generate standard scores or normal deviates (z-scores), and then meta-
803 analyzed using METAL in a fixed-effects model with inverse-variance weighting of regression
804 coefficients¹¹⁹. In a first round of meta-analysis, ancestry-specific summary statistics were
805 generated, which then served as input for a subsequent round of meta-analysis that represents
806 the trans-ancestry effects of our lead SNPs on quantitative hepatic fat.

807

808 *External validation in a Liver Biopsy cohort*

809 Available data from the following groups contributed to the Liver Biopsy Cohort.

810 Non-Alcoholic Steatohepatitis Clinical Research Network (NASH CRN) studies with Hispanic
811 Boys, FLINT, PIVENS and NASH Women Studies: Results from several studies of EA and HISP
812 participants were included from the Lundquist Institute. The Hispanic American cases are
813 derived from the NAFLD Pediatric Database I (NAFLD Peds DB1), a prospective, longitudinal,
814 multicenter, observational study cohort of adults and children initiated in 2002 and contains
815 over 4,400 subjects¹²³. Clinical and histologic features of database participants have been
816 described by Patton et al¹²⁴. Biopsy specimens were reviewed and scored centrally by the Non-
817 Alcoholic Steatohepatitis Clinical Research Network (NASH CRN) Pathology Committee
818 according to the histology scoring system established by the NASH CRN¹²⁵. Genotyping was
819 performed using the Illumina HumanCNV370-Quadv3 BeadChip at the Medical Genetics
820 Institute at Cedars–Sinai Medical Center (HumanCNV370-Quadv3 BeadChips; Illumina, San
821 Diego, CA, USA). The Hispanic American controls from NASH-CRN are derived from the Long QT
822 Screening (LQTS) study¹²⁶. Saliva samples were used for genotyping with the Illumina
823 HumanCore-24 BeadChips at the Institute for Translational Genomics and Population Sciences
824 of the Lundquist Institute at Harbor-UCLA Medical Center. For all Hispanic American samples,
825 SNP data were imputed to the 1000 Genomes Project phase 3 dataset version 5 (AMR
826 population) on the Michigan imputation server. The final dataset consisted of 787 samples,
827 including 208 cases from NASH Boys and 579 controls from LQTS, and the top 3 PCs were
828 included in the association analysis. The NASH CRN database and clinical trials were reviewed
829 and approved by the individual institutional review boards at each participating site. All
830 participants signed an informed consent prior to their enrollment into these consents and their
831 de-identified genetic data to be used for future liver disease research by the NASH CRN

832 investigators and by their collaborators. These studies have been monitored by an NIDDK-
833 sponsored data safety and monitoring board.

834 The European American NAFLD samples from Lundquist Institute are derived from
835 FLINT, PIVENS, and NASH women studies, and the controls are derived from the Cholesterol
836 and Atherosclerosis Pharmacogenetics (CAP) trial. The details of the FLINT study have been
837 published previously¹²⁷. Liver histology was blindly and centrally assessed by the NASH Clinical
838 Research Network (NASH CRN) Pathology Committee according to the NASH CRN system¹²⁵. A
839 total of 244 patients with available DNA were genotyped of whom 198 (81%) were White¹²⁸.
840 Genotyping was performed using the Omni2.5 content GWAS chip. The PIVENS study, a study of
841 Pioglitazone versus Vitamin E versus Placebo in non-diabetic adults has been described
842 previously⁷¹. Genotyping was performed on 432 PIVENS samples along with the FLINT samples
843 using the Omni2.5 content GWAS chip. Subjects were removed for failed genotyping,
844 unresolvable gender discrepancies, being outliers by principal component analyses, and by
845 relatedness. In total, 197 White samples remained in the analysis dataset. The NASH Women
846 study included a subset of patients who were into the NAFLD Database Study of NASH CRN
847 whose liver biopsy specimens were reviewed and scored centrally by the NASH CRN Pathology
848 Subcommittee. For the GWAS ancillary study²² genotyping was performed at the Medical
849 Genetics Institute at Cedars–Sinai Medical Center with the use of Infinium HD technology
850 (HumanCNV370-QuadV3 BeadChips; Illumina, San Diego, CA). The controls for the European
851 American analysis from Lundquist Institute are derived from the CAP trial involved 944 healthy
852 volunteers, 609 of whom were Caucasian¹²⁹. In total, 591 subjects were genotyped on the
853 Illumina HumanHap300 BeadChip or Illumina HumanCNV610-Quad beadchip. Imputation was

854 performed using the Michigan Imputation Server with the reference panel of the Haplotype
855 Reference Consortium (HRC) 1.1 release in 2016. After final QC of European American cohorts,
856 the final 1,225 samples in the analysis including 650 cases and 575 controls, and the top 3 PCs
857 for genetic ancestry were included in the association analysis.

858 EPoS Consortium Cohort: Results from EPoS consortium cohort were included from Newcastle
859 University. A total 1,483 histologically characterized NAFLD cases were included and 17,781
860 genetically matched controls, with the cases recruited into the European NAFLD Registry
861 (ClinicalTrials.gov Identifier: NCT04442334) from clinics at several leading European tertiary
862 liver centres²⁰. Details of inclusion/exclusion criteria have previously been described^{20,130}. All
863 patients had undergone liver biopsy as part of the routine diagnostic workup for presumed
864 NAFLD, and routinely assessed according to accepted criteria by experienced liver pathologists
865 and scored using the well validated NIDDK NASH-CRN system¹²⁵. Genotyping was performed
866 using the Illumina OmniExpress BeadChip by Edinburgh Clinical Research Centre. The 17,781
867 population controls were recruited from existing genome-wide genotype data: Wellcome Trust
868 Case Control Consortium, (n=5,159) typed on the Illumina Human1.2M-Duo; the Hypergenes
869 cohort (n=1,520) typed on the Illumina Human1M-Duo, KORA (n=1,835) genotyped on the
870 Illumina HumanOmni2.5 Exome chip, and Understanding Societies (n=9,267) typed on the
871 Illumina HumanCoreExome chip. Overlapping SNPs that were well genotyped in all case and
872 control cohorts were imputed together to the Haplotype Resource Consortium panel (HRC 1.1r
873 2016) by the Michigan Imputation Server.

874 The Geisinger Health System (GHS) bariatric surgery cohort: This consisted of 3,599 individuals
875 of European American descent. Wedge biopsies of the liver were obtained intraoperatively

876 during bariatric surgery, and liver histology was conducted by an experienced pathologist and
877 subsequently re-reviewed by a second experienced pathologist using the NASH CRN scoring
878 system¹²⁵. A total of 806 participants did not have NAFLD and were classified as controls,
879 whereas 2,793 were histologically characterized as having NAFLD. DNA sample preparation and
880 whole-exome sequencing were performed at the Regeneron Genetics Centre¹³¹. Exome capture
881 was performed using NimbleGen probes according to the manufacturer's recommended
882 protocol (Roche NimbleGen) multiplexed samples were sequenced on an Illumina v4 HiSeq
883 2500. Raw sequence data from each run were uploaded to the DNAnexus platform for
884 sequence read alignment and variant identification.

885 STELLAR-3 and ATLAS studies: Results from two trials from Gilead Sciences were included
886 including phase 3 STELLAR-3 study (ClinicalTrials.gov Identifier: NCT03053050), and phase 2
887 ATLAS study (ClinicalTrials.gov Identifier: NCT03449446) which were
888 discontinued/terminated¹³². Genotyping was performed using whole genome sequencing
889 (Illumina) aimed at 100x coverage. The PyVCF script was used to extract allele frequencies from
890 VCF files generated using GATK4 pipeline with hg38 as reference genome.

891 BioVU Biorepository: BioVU subjects at Vanderbilt University underwent SNP genotyping using
892 the Illumina Infinium Multi-Ethnic Genotyping Array (MEGAEX) platform and underwent QC
893 analyses and imputation as previously described¹³³. Genetic data for were imputed using the
894 Michigan Imputation Server (HRC v1.1) and genotyping data was linked to de-identified EHR
895 data. All available lab measurements in this cohort that occurred when the subject was at least
896 18 years of age. BioVU participants were selected based on available pathology report for liver
897 biopsy in the note table in Observational Medical Outcomes Partnership (OMOP), excluding

898 those with other conflicting diagnoses (e.g. viral hepatitis, alcohol, transplant, explant). NAFLD
899 was defined based on pathology report defining hepatic fat as mild, moderate, severe, 5% or
900 more.

901
902 Control subjects within BloVU were identified by selecting those with ALT levels below 30 for
903 males and below 20 for females. Both cases and controls were excluded for alcohol use
904 disorders using ICD-9 and -10 codes.

905
906 Penn Medicine Biobank (PMBB): The Penn Medicine Biobank includes participants recruited
907 from the University of Pennsylvania Health System. A total of 139 biopsy proven NAFLD cases
908 were selected using Linguamatics natural language processing on biopsy protocols of the PENN
909 EHR. Cases were then linked to the PennMedicine BioBank. In addition, 1,995 PMBB
910 participants were classified as controls if a recent CT scan of the liver was available, but no
911 steatosis was present. Appropriate consent was obtained from each participant regarding
912 storage of biological specimens, genetic sequencing, and access to all available EHR data. DNA
913 extracted from the blood plasma of 2,134 samples were genotyped in three batches: the
914 Illumina QuadOmni chip at the Regeneron Genetics Center; the Illumina GSA V1 chip OR on the
915 Illumina GSA V2 chip by the Center for Applied Genomics at the Children's Hospital of
916 Philadelphia. Genotypes for each of the three PMBB datasets were imputed to the 1000
917 Genomes reference panel (1000G Phase3 v5) using the Michigan Imputation Server. Results
918 from liver biopsy data are shown in **Supplemental Tables 6 and 7**.

919

920 *Heritability estimates and genetic correlations analysis.*

921 LD-score regression was used to estimate the heritability coefficient, and subsequently
922 population and sample prevalence estimates were applied to estimate heritability on the
923 liability scale¹³⁴. A genome-wide genetic correlation analysis was performed to investigate
924 possible co-regulation or a shared genetic basis between cALT and other complex traits and
925 diseases (**Supplementary Table 9**). Pairwise genetic correlation coefficients were estimated
926 between the meta-analyzed NAFLD GWAS summary output in EA and each of 774 precomputed
927 and publicly available GWAS summary statistics for complex traits and diseases by using LD
928 score regression through LD Hub v1.9.3 (<http://ldsc.broadinstitute.org>). Statistical significance
929 was set to a Bonferroni-corrected level of $P < 6.5 \times 10^{-5}$.

930

931 *Tissue- and epigenetic-specific enrichment of NAFLD heritability.*

932 We analyzed cell type-specific annotations to identify enrichments of NAFLD heritability as
933 shown in **Supplementary Table 16**. First, a baseline gene model was generated consisting of 53
934 functional categories, including UCSC gene models, ENCODE functional annotations¹³⁵,
935 Roadmap epigenomic annotations¹³⁶, and FANTOM5 enhancers¹³⁷. Gene expression and
936 chromatin data were also analyzed to identify disease-relevant tissues, cell types, and tissue-
937 specific epigenetic annotations. We used LDSC³⁷⁻³⁹ to test for enriched heritability in regions
938 surrounding genes with the highest tissue-specific expression. Sources of data that were
939 analyzed included 53 human tissue or cell type RNA-seq data from GTEx²⁸; human, mouse, or
940 rat tissue or cell type array data from the Franke lab¹³⁸; 3 sets of mouse brain cell type array
941 data from Cahoy *et al*¹³⁹; 292 mouse immune cell type array data from ImmGen¹⁴⁰; and 396

942 human epigenetic annotations from the Roadmap Epigenomics Consortium¹³⁶. Expression
943 profiles are considered statistically significantly enriched for cALT susceptibility if they pass the
944 nominal P-value threshold of 0.003.

945

946 *Pathway Annotation enrichment.*

947 Enrichment analyses in DEPICT¹⁴¹ were conducted using genome-wide significant ($P < 5 \times 10^{-8}$)
948 NAFLD GWAS lead SNPs (**Supplementary Table 18**). DEPICT is based on predefined phenotypic
949 gene sets from multiple databases and Affymetrix HGU133a2.0 expression microarray data
950 from >37k subjects to build highly-expressed gene sets for Medical Subject Heading (MeSH)
951 tissue and cell type annotations. Output includes a P-value for enrichment and a yes/no
952 indicator of whether the FDR q-value is significant ($P < 0.05$). Tissue and gene-set enrichment
953 features are considered. We tested for epigenomic enrichment of genetic variants using
954 GREGOR software (**Supplementary Table 19**)¹⁴². We selected EA-specific NAFLD lead variants
955 with a p-value less than 5×10^{-8} . We tested for enrichment of the resulting GWAS lead variants
956 or their LD proxies (r^2 threshold of 0.8 within 1 Mb of the GWAS lead, 1000 Genomes Phase I) in
957 genomic features including ENCODE, Epigenome Roadmap, and manually curated data
958 (**Supplemental Table 20**). Enrichment was considered significant if the enrichment p-value was
959 less than the Bonferroni-corrected threshold of $P = 1.8 \times 10^{-5}$ ($0.05/2,725$ tested features).

960

961 *Coding variant mapping.*

962 All imputed variants in MVP were evaluated with Ensemble variant effect predictor¹⁴³, and all
963 predicted LoF and missense variants were extracted. The LD was calculated with established

964 variants for trans-ancestry, EA, AA, and HISP lead SNPs based on 1000 Genomes reference
965 panel¹⁴⁴. For SNPs with low allele frequencies, the MVP dataset was used for LD calculation for
966 the respective underlying population. For the trans-ancestry coding variants, the EA panel was
967 used for LD calculation. Coding variants that were in strong LD ($r^2 > 0.7$) with lead SNPs and had
968 a strong statistical association ($P\text{-value} < 1 \times 10^{-5}$) were considered the putative causal drivers of
969 the observed association at the respective locus (**Supplementary Table 22**).

970

971

972

973 *Colocalization with gene expression*

974 GWAS summary statistics were lifted over from GRCh37 to GRCh38 using LiftOver
975 (<https://genome.ucsc.edu/cgi-bin/hgLiftOver>). Colocalization analysis was run separately for
976 eQTLs and sQTLs for each of the 49 tissues in GTEx v8 (**Supplementary Tables 23 and 24**)²⁸. For
977 each tissue, we obtained an LD block for the genome with a sentinel SNP at $P < 5 \times 10^{-8}$, and then
978 restricted analysis to the LD blocks. For each LD block with a sentinel SNP, all genes within 1Mb
979 of the sentinel SNP (cis-Genes) were identified, and then restricted to those that were
980 identified as eGenes in GTEx v8 at an FDR threshold of 0.05 (cis-eGenes). For each cis-eGene,
981 we performed colocalization using all variants within 1Mb of the gene using the default prior
982 probabilities in the 'coloc' function for the coloc package in R. We first assessed each coloc
983 result for whether there was sufficient power to test for colocalization ($PP3+PP4>0.8$), and for
984 the colocalization pairs that pass the power threshold, we defined the significant colocalization
985 threshold as $PP4/(PP3+PP4)>0.9$.

986

987 *Overlap with open chromatin.*

988 At each of the 77 NAFLD-associated loci from the trans-ancestry meta-analysis, we looked for
989 overlaps between any variant in the credible set, and regions of open chromatin previously
990 identified using ATAC-Seq experiments in two cell types—3 biological replicates of HepG2¹⁴⁵
991 and 3 biological replicates of hepatocyte-like cells (HLC)¹⁴⁶ produced by differentiating three
992 biological replicates of iPSCs, which in turn were generated from peripheral blood mononuclear
993 cells using a previously published protocol⁴⁴. Results are shown in **Supplementary Table 25**.

994

995 *Overlap with Promoter Capture-C data.*

996 We used two promoter Capture-C datasets from two cell/tissue types to capture physical
997 interactions between gene promoters and their regulatory elements and genes; three biological
998 replicates of HepG2 liver carcinoma cells, and hepatocyte-like cells (HLC)¹⁴⁵. The detailed
999 protocol to prepare HepG2 or HLC cells for the promoter Capture-C experiment is previously
1000 described⁴⁴. Briefly, for each dataset, 10 million cells were used for promoter Capture-C library
1001 generation. Custom capture baits were designed using an Agilent SureSelect library design
1002 targeting both ends of DpnII restriction fragments encompassing promoters (including
1003 alternative promoters) of all human coding genes, noncoding RNA, antisense RNA, snRNA,
1004 miRNA, snoRNA, and lincRNA transcripts, totaling 36,691 RNA baited fragments. Each library
1005 was then sequenced on an Illumina NovoSeq (HLC), or Illumina HiSeq 4000 (HLC), generating
1006 1.6 billion read pairs per sample (50 base pair read length.) HiCUP¹⁴⁷ was used to process the
1007 raw FastQ files into loop calls; we then used CHiCAGO¹⁴⁸ to define significant looping

1008 interactions; a default score of 5 was defined as significant. We identified those NAFLD loci at
1009 which at least one variant in the credible set interacted with an annotated bait in the Capture-C
1010 data (**Supplementary Table 25**).

1011
1012 *Protein-Protein Interaction Network Analysis*
1013 We employed the search tool for retrieval of interacting genes (STRING) v11¹⁴⁹ ([https://string-](https://string-db.org)
1014 [db.org](https://string-db.org)) to seek potential interactions between nominated genes. STRING integrates both
1015 known and predicted PPIs and can be applied to predict functional interactions of proteins. In
1016 our study, the sources for interaction were restricted to the ‘Homo Sapiens’ species and limited
1017 to experimentally validated and curated databases. An interaction score ≥ 0.4 were applied to
1018 construct the PPI networks, in which the nodes correspond to the proteins and the edges
1019 represent the interactions (**Figure 4, Supplemental Table 26**).

1020
1021 *Ensemble variant-to-gene mapping to identify putative causal genes.*
1022 Based on DEPICT gene prediction, coding variant linkage analysis, QTL analysis, and annotation
1023 enrichment, and PPI networks (**Supplemental Tables 18-26**), a total of 215 potentially relevant
1024 genes for NAFLD were mapped to trans-ancestry 77 loci. For each locus, we counted how many
1025 times each gene in that region was identified in the 8 analyses. We then divided this number by
1026 the total number of experiments (i.e., 8) to calculate an evidence burden (called nomination
1027 score) that ranges from 0 to 100%. For each genomic locus, the gene that was most frequently
1028 identified as a causal gene was selected as the putative causal gene for that locus. In the case of
1029 a tie break, and if the respective genes have identical nomination profiles, the gene with eQTLs

1030 in multiple tissues was selected as the putative causal gene. Similarly, gene nomination was
1031 preferred for loci that strongly tagged ($r^2 > 0.8$) a coding variant. Loci that scored with 3 distinct
1032 sources of evidence or greater are listed for coding variant (**Table 1A**) and non-coding variants
1033 (**Table 1B**), respectively.

1034

1035 *MVP LabWAS.*

1036 A total of 21 continuous traits in the discovery MVP dataset, e.g. AST, ALP, fasting TG, HDL, LDL,
1037 TC, random glucose, HbA1c, albumin, bilirubin, platelet count, BMI, blood urea nitrogen (BUN),
1038 creatinine, eGFR, SBP, DBP, ESR, INR, and C-reactive protein were tested in 186,681 EA's with
1039 association of 77 SNPs using linear regression of log-linear values. Covariates included age,
1040 gender and the first 10 PC's of EA ancestry (**Supplementary Table 29**). The Bonferonni p-value
1041 threshold is set at 3.09×10^{-05} ($0.05 / 21 \text{ traits} * 77 \text{ SNPs}$)

1042

1043 *PheWAS with UK Biobank data.*

1044 For the 77 lead trans-ancestry SNPs and EA and AA specific SNPs, we performed a PheWAS in a
1045 genome-wide association study of EHR-derived ICD billing codes from the White British
1046 participants of the UK Biobank using PheWeb¹⁵⁰. In short, phenotypes were classified into 1,403
1047 PheWAS codes excluding SNP-PheWAS code association pairs with case counts less than fifty¹⁵¹.
1048 All individuals were imputed using the Haplotype Reference Consortium panel¹⁵², resulting in
1049 the availability of 28 million genetic variants for a total of 408,961 subjects. Analyses on binary
1050 outcomes were conducted using a model named SAIGE, adjusted for genetic relatedness,
1051 gender, year of birth and the first 4 PC's of white British genetic ancestry¹⁵³. SAIGE stands for

1052 Scalable and Accurate Implementation of GEneralized mixed model and represents a
1053 generalized mixed-model association test that accounts for case-control imbalance and sample
1054 relatedness¹⁵³. Results are shown in **Supplemental Tables 30 and 31**. SNP-trait associations are
1055 listed if they passed a nominal significance threshold of $P < 0.001$, and are considered Bonferoni
1056 significant when $P < 4.6 \times 10^{-7}$ ($0.05 / 77 \text{ SNPs} * 1,403 \text{ traits}$).

1057

1058 *IEU OpenGWAS project SNP lookup.*

1059 An additional phenome-wide lookup was performed for 77 lead trans-ancestry SNPs and EA and
1060 AA specific SNPs in Bristol University's MRC Integrative Epidemiology Unit (IEU) GWAS
1061 database¹⁵⁴. This database consists of 126,114,500,026 genetic associations from 34,494 GWAS
1062 summary datasets, including UK Biobank (<http://www.nealelab.is/uk-biobank>), FinnGen
1063 (<https://github.com/FINNGEN/pheweb>), Biobank Japan (<http://jenger.riken.jp/result>), the
1064 NHGRI-EBI GWAS catalog (<https://www.ebi.ac.uk/gwas>), a large-scale blood metabolites
1065 GWAS¹⁵⁵, circulating metabolites GWAS¹⁵⁶, the MR-Base manually curated database¹⁵⁷, and a
1066 protein level GWAS¹⁵⁸. Results are shown in **Supplemental Table 32**.

1067

1068 *Regional cardiometabolic cross-trait colocalization.*

1069 Bayesian colocalization tests between NAFLD-associated signals and the following trait- and
1070 disease-associated signals were performed using the COLOC R package¹⁵⁹. To enable cross-trait
1071 associations, we compiled summary statistics of 36 cardiometabolic and blood cell-related
1072 quantitative traits and disease from GWAS studies conducted in EA ancestry individuals, and for
1073 MVP-based reports also on AA and HISP. To summarize, for total, HDL, and LDL cholesterol,

1074 triglycerides, alcohol use disorder, alcohol intake, systolic blood pressure, diastolic blood
1075 pressure, type 2 diabetes, BMI, CAD, we used the summary statistics available from various
1076 MVP-based studies^{27,116,160}. Of these, the summary statistics for CAD and BMI GWAS in MVP
1077 have not been published or deposited as of yet. Data on WHR were derived from GIANT
1078 Consortium¹⁶¹, whereas summary statistics on CKD, gout, blood urea nitrogen, urate, urinary
1079 albumin-to-creatinine ratio, microalbuminuria, and eGFR were derived from CKD Genetics
1080 Consortium¹⁶²⁻¹⁶⁴. Finally, summary statistics of blood cell traits (e.g. platelet count, albumin,
1081 white blood cells, basophils, eosinophils, neutrophils, hemoglobin, hematocrit, immature
1082 reticulocyte fraction, lymphocytes, monocytes, reticulocytes, mean corpuscular hemoglobin,
1083 mean corpuscular volume, mean platelet volume, platelet distribution width, and red cell
1084 distribution width) were derived from a large-scale GWAS report performed in UK Biobank and
1085 INTERVAL studies¹⁶⁵. A colocalization test was performed for all 77 NAFLD loci spanning 500kb
1086 region around the lead SNP for all 36 compiled traits. For each association pair COLOC was run
1087 with default parameters and priors. COLOC computed posterior probabilities for the following
1088 five hypotheses: PP0, no association with trait 1 (cALT GWAS signal) or trait 2 (e.g., co-
1089 associated metabolic signal); PP1, association with trait 1 only (i.e., no association with trait 2);
1090 PP2, association with trait 2 only (i.e., no association with trait 1); PP3, association with trait 1
1091 and trait 2 by two independent signals; and PP4, association with trait 1 and trait 2 by shared
1092 variants. Evidence of colocalization¹⁶⁶ was defined by $PP3 + PP4 \geq 0.99$ and $PP4/PP3 \geq 5$. Results
1093 are shown in **Supplemental Table 33**.

1094

1095 *Genetic risk scores and histologically characterized NAFLD.*

1096 We constructed genetic risk scores (GRS) in 4 histologically characterized cohorts (e.g.
1097 Lundquist Whites and Hispanic Americans, EPoS Consortium Whites, and BioVU Whites) by
1098 calculating a linear combination of weights derived from the MVP dataset of lead 77 trans-
1099 ancestry cALT variants that passed conventional genome-wide significance (GRS-77, $P < 5.0 \times 10^{-8}$).
1100 The GRS-77 was standardized and the risk of histologically characterized NAFLD was assessed
1101 using a logistic regression model together with the potential confounding factors of age,
1102 gender, and the first 3 to 5 principal components of ancestry. To delineate the potential driving
1103 effects of known NAFLD loci, we divided the 77 loci into two sets, and generated one PRS
1104 consisting of 9 known NAFLD SNPs only (GRS-9), and one of newly identified 68 cALT SNPs (GRS-
1105 68). The goal of this separation is to evaluate whether a GRS based on novel SNPs alone (GRS-
1106 68) showed predictive capability for biopsy-proven histologically characterized NAFLD. Both
1107 GRS's were added as independent predictors in a logistic regression model to explain
1108 histologically characterized NAFLD with the confounders of age, gender, and PC's of ancestry.
1109 The individual effect sizes for each study were then meta-analyzed using the metagen package
1110 in R with random effects model comparing the standardized mean difference (SMD, mean
1111 differences divided by their respective standard deviations) (**Supplemental Table 9B**). A forest
1112 plot was created to visualize the effect estimates between the studies (**Supplemental Figure**
1113 **10**). In similar fashion, SNPs were divided into 3 groups according to replication power, where
1114 SNPs were divided into a Bonferroni-replicated GRS consisting of 17 SNPs, a nominally
1115 significant with directional concordance GRS with 25 SNPs, and non-replicated GRS with 35
1116 SNPs (**Supplemental Table 9C, Supplemental Figure 11**). Finally, a GRS subset was created
1117 based on the pleiotropy analysis and Venn Diagram, where we generated subset GRS that

1118 reflects liver+metabolic (17 SNPs), liver+metabolic+inflammation (38 SNPs), liver+inflammation
1119 (5 SNPs), and liver only strata (17 SNPs) (**Supplemental Table 9D, Supplemental Figure 14**).

1120

1121 *Transcription Factor Analysis.*

1122 We identified nominated genes (**Supplemental Table 28**) that encode for TFs based on known
1123 motifs, inferred motifs from similar proteins, and likely sequence specific TFs according to
1124 literature or domain structure¹⁶⁷. Target genes for these TFs were extracted using DoRothEA
1125 database¹⁶⁸ in OmniPath collection¹⁶⁹ using the associated Bioconductor R package
1126 OmnipathR¹⁷⁰, a gene set resource containing TF-TF target interactions curated from public
1127 literature resources, such as ChIP-seq peaks, TF binding site motifs and interactions inferred
1128 directly from gene expression.

1129

1130 *Directional Pleiotropy and Gene Cluster Analysis.*

1131 We used the R package ‘pheatmap’ for a stratified agglomerative hierarchical clustering
1132 method named ‘complete linkage’, where each element is its own cluster at the beginning, and
1133 two clusters of the shortest distance in between them are sequentially combined into larger
1134 clusters until all elements are included in one single cluster, where distance is measured in
1135 Euclidean distance. We used the 77 lead SNPs and their corresponding single-trait effect
1136 estimates for 20 traits corresponding to 3 biological super groups (e.g. lipids, inflammation,
1137 metabolic) as input, with the sign of each cell determined by direction of effect, and the
1138 strength by the $-\log_{10}(\text{p-value})$. The alleles were oriented as such that the cALT-increasing
1139 allele was set to the effect allele, which allows for direct comparison of the various association

1140 profiles. We selected the default ‘complete’ method and ‘Euclidean’ distance options to
1141 perform hierarchical clustering, stratified by the 3 super groups of metabolic, inflammation, and
1142 lipid traits. The results of the clustering gene set are visualized with a dendrogram on the left
1143 side of the heatmap, which is broadly grouped into 7 distinct gene clusters.

1144

1145 **Acknowledgements**

1146 This research is based on data from the Million Veteran Program, Office of Research and
1147 Development, Veterans Health Administration and was supported by award no. MVP000. This
1148 publication does not represent the views of the Department of Veterans Affairs, the US Food
1149 and Drug Administration, or the US Government. This research was also supported by funding
1150 from: the Department of Veterans Affairs awards I01- BX003362 (P.S.T. and K.M.C) and
1151 I01BX003341 (H.R.K. Co-Principal Investigator) and the VA Informatics and Computing
1152 Infrastructure (VINCI) VA HSR RES 130457 (S.L.D). B.F.V. acknowledges support for this work
1153 from the NIH/NIDDK (DK101478 and DK126194) and a Linda Pechenik Montague Investigator
1154 award. K.M.C, S.M.D, J.M.G, C.J.O, L.S.P, and P.S.T. are supported by the VA Cooperative Studies
1155 Program. S.M.D. is supported by the Veterans Administration [IK2 CX001780]. Funding support
1156 is also acknowledged for M.S. (K23 DK115897), R.M.C (R01 AA026302), D.K. (National Heart,
1157 Lung, and Blood Institute of the National Institutes of Health [T32 HL007734]), J.B.M
1158 (R01HL151855, UM1DK078616), L.S.P. (VA awards I01 CX001025, and I01 CX001737, NIH
1159 awards R21 DK099716, U01 DK091958, U01 DK098246, P30 DK111024, and R03 AI133172, and
1160 a Cystic Fibrosis Foundation award PHILLI12A0). The Rader lab was supported by NIH grants
1161 HL134853 (NJH and DJR) and DK114291-01A1 (K.T.C, N.J.H, and D.J.R). We thank all study

1162 participants for their contribution. Support for imaging studies was provided by ITMAT (NIH
1163 NCATS UL1TR001878), the Penn Center for Precision Medicine Accelerator Fund and R01
1164 HL137501. Data for external replication and hepatic fat concordance were provided by
1165 investigators using United Kingdom BioBank, Multi-Ethnic Study of Atherosclerosis (MESA), Old
1166 Order Amish Study (Amish), Framingham Heart Study (FHS) and Penn Medicine Biobank
1167 (PMBB).

1168

1169 **MESA/MESA SHARe Acknowledgements:** MESA and the MESA SHARe projects are conducted
1170 and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with
1171 MESA investigators. This research was supported by R01 HL071739 and MESA was supported
1172 by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-
1173 HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162,
1174 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-
1175 HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-
1176 TR-001079, UL1-TR-001420. Also supported in part by the National Center for Advancing
1177 Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and
1178 Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern
1179 California Diabetes Endocrinology Research Center.

1180

1181 **NASH-CRN Acknowledgements:** The NASH Boys study was supported by NIDDK (U01DK061734,
1182 U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061737, U01DK061738,
1183 U01DK061730, U01DK061713) and NICHD. It was also supported by NIH CTSA awards

1184 (UL1TR000040, UL1RR024989, UL1RR025761, M01RR00188, UL1RR024131, UL1RR025014,
1185 UL1RR031990, UL1RR025741, UL1RR029887, UL1RR24156, UL1RR025055, UL1RR031980), and
1186 DRC HDK063491. LQTS was supported by the National Institutes of Health (grant
1187 5R42HL112435-04 to QT Medical, Inc.). The provision of genotyping data was supported in part
1188 by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the
1189 National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC)
1190 grant DK063491 to the Southern California Diabetes Endocrinology Research Center. For LQTS:
1191 QT Medical, Inc., was involved in the study design and collection of data. However, QT Medical,
1192 Inc., had no involvement in the analysis and interpretation of the data, the drafting of the
1193 article, or the decision to submit the article for publication. The FLINT trial was conducted by
1194 the NASH CRN and supported in part by a Collaborative Research and Development Agreement
1195 (CRADA) between NIDDK and Intercept Pharmaceuticals. The Nonalcoholic Steatohepatitis
1196 Clinical Research Network (NASH CRN) is supported by the National Institute of Diabetes and
1197 Digestive and Kidney Diseases (NIDDK) (grants U01DK061718, U01DK061728, U01DK061731,
1198 U01DK061732, U01DK061734, U01DK061737, U01DK061738, U01DK061730, U01DK061713).
1199 Additional support is received from the National Center for Advancing Translational Sciences
1200 (NCATS) (grants UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448, UL1TR000100,
1201 UL1TR000004, UL1TR000423, UL1TR000058). The PIVENS study was supported by grants from
1202 the National Institutes of Health to the NASH Clinical Research Network (U01DK61718,
1203 U01DK61728, U01DK61731, U01DK61732, U01DK61734, U01DK61737, U01DK61738,
1204 U01DK61730, U01DK61713) and, in part, by the intramural program on the NIH, National
1205 Cancer Institute. Other grant support includes the following National Institutes of Health

1206 General Clinical Research Centers or Clinical and Translational Science Awards: UL1RR024989,
1207 UL1RR024128, M01RR000750, UL1RR024131, M01RR000827, UL1RR025014, M01RR000065.
1208 Additional funding to conduct PIVENS trial was provided by Takeda Pharmaceuticals North
1209 America, Inc. through a Cooperative Research and Development Agreement (CRADA) with the
1210 National Institutes of Health. The vitamin E softgels and matching placebo were provided by
1211 Pharmavite, LLC through a Clinical Trial Agreement with the National Institutes of Health. The
1212 NASH women study was supported by U01DK061737 and K24DK069290 (N.C.), NCRR grant
1213 M01-RR00425 to the Cedars-Sinai General Research Center Genotyping core, P30DK063491 to
1214 J.R., and R01DK079888 to M.O.G. This work is supported in part by the American
1215 Gastroenterological Association (AGA) Foundation, Sucampo, ASP Designated Research Award
1216 in Geriatric Gastroenterology, and by a T. Franklin Williams Scholarship Award; Funding
1217 provided by Atlantic Philanthropies, Inc, the John A. Hartford Foundation, the Association of
1218 Specialty Professors, and the American Gastroenterological Association to R.L. This research
1219 was funded in part with the support of the UCSD Digestive Diseases Research Development
1220 Center, US PHS grant DK080506.

1221 The CAP study was supported by the National Institutes of Health: grant U19 HL069757 from
1222 the National Heart, Lung, and Blood Institute; and grant UL1TR000124 from the National Center
1223 for Advancing Translational Sciences.

1224
1225 **EPoS Acknowledgements:** The EPoS genetics study and the European NAFLD Registry have
1226 been supported by the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by
1227 the European Union Horizon 2020 Framework Program of the European Union under Grant

1228 Agreement 634413, the FLIP (Fatty Liver: Inhibition of Progression) consortium funded by the
1229 (European Union FP7 under grant agreement 241762), the LITMUS (Liver Investigation: Testing
1230 Marker Utility in Steatohepatitis) consortium funded by the European Union Innovative
1231 Medicines Initiative 2 Joint Undertaking that receives support from the European Union's
1232 Horizon 2020 research and innovation programme and EFPIA under grant agreement 777377,
1233 and the Newcastle NIHR Biomedical Research Centre.

1234

1235 **Gilead Acknowledgements:** The Stellar and Atlas were funded by Gilead Sciences, Inc.

1236

1237 **Regeneron Acknowledgements:** The Geisinger Health System bariatric-surgery biobank was
1238 funded by Regeneron Pharmaceuticals and partly supported by a grant (P30DK072488) from
1239 the Mid-Atlantic Nutrition Obesity Research Center by the National Institutes of Health (NIH).

1240

1241 **Penn Medicine Biobank Acknowledgements:** The Penn Medicine BioBank is funded by the
1242 Perelman School of Medicine at the University of Pennsylvania and by a gift from the Smilow
1243 family, and the National Center for Advancing Translational Sciences of the National Institutes
1244 of Health under CTSA Award Number UL1TR001878."

1245

1246 **BioVU Acknowledgements:** The Vanderbilt University Medical Center's BioVU projects are
1247 supported by institutional funding, private agencies, and federal grants, which include the NIH
1248 funded Shared Instrumentation Grant S10OD017985 and S10RR025141; CTSA grants
1249 UL1TR002243, UL1TR000445, and UL1RR024975; and investigator-led projects U01HG004798,

1250 R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711;

1251 U01 HG004603; U01 HG006378.

1252

1253 **Ethics statement**

1254 The Central Veterans Affairs Institutional Review Board (IRB) and site-specific Research and

1255 Development Committees approved the Million Veteran Program study. All other cohorts

1256 participating in this meta-analysis have ethical approval from their local institutions. All relevant

1257 ethical regulations were followed.

1258

1259

1260 **Data availability**

1261 The full summary level association data from the trans-ancestry, European American, African

1262 American, Hispanic American, and Asian American meta-analysis from this report will be

1263 available through dbGAP (Accession codes will be available before publication).

1264

1265 **Disclosures**

1266 H.R.K. is a member of a Dicerna scientific advisory board; a member of the American Society of

1267 Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which during the past three

1268 years was supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna,

1269 Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka; and is named as an inventor on PCT

1270 patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed

1271 January 24, 2018. D.G. is employed part-time by Novo Nordisk.

1272 **References**

- 1273 1. Asrani, S.K., Devarbhavi, H., Eaton, J. & Kamath, P.S. Burden of liver diseases in the world. *J*
1274 *Hepatol* **70**, 151-171 (2019).
- 1275 2. Younossi, Z., Anstee, Q.M. & Marietti, M. Global burden of NAFLD and NASH: trends,
1276 predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol* **15**(2018).
- 1277 3. Carr, R.M., Oranu, A. & Khungar, V. Nonalcoholic Fatty Liver Disease: Pathophysiology and
1278 Management. *Gastroenterol Clin North Am* **45**, 639-652 (2016).
- 1279 4. Chalasani, N. *et al.* The diagnosis and management of nonalcoholic fatty liver disease: Practice
1280 guidance from the American Association for the Study of Liver Diseases. *Hepatology* **67**, 328-357
1281 (2018).
- 1282 5. Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M. & Sanyal, A.J. Mechanisms of NAFLD
1283 development and therapeutic strategies. *Nat Med* **24**, 908-922 (2018).
- 1284 6. Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A.J. Modeling the epidemic of
1285 nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
1286 *Hepatology* **67**, 123-133 (2018).
- 1287 7. Sookoian, S. & Pirola, C.J. Genetic predisposition in nonalcoholic fatty liver disease. *Clin Mol*
1288 *Hepatol* **23**, 1-12 (2017).
- 1289 8. Jarvis, H. *et al.* Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty
1290 liver disease (NAFLD): A systematic review and meta-analysis of population-based observational
1291 studies. *PLoS Med* **17**, e1003100 (2020).
- 1292 9. Romeo, S. *et al.* Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver
1293 disease. *Nat Genet* **40**, 1461-5 (2008).
- 1294 10. Yuan, X. *et al.* Population-based genome-wide association studies reveal six loci influencing
1295 plasma levels of liver enzymes. *Am J Hum Genet* **83**, 520-8 (2008).
- 1296 11. Chambers, J.C. *et al.* Genome-wide association study identifies loci influencing concentrations of
1297 liver enzymes in plasma. *Nat Genet* **43**, 1131-8 (2011).
- 1298 12. Speliotes, E.K. *et al.* Genome-wide association analysis identifies variants associated with
1299 nonalcoholic fatty liver disease that have distinct effects on metabolic traits. *PLoS Genet* **7**,
1300 e1001324 (2011).
- 1301 13. Feitosa, M.F. *et al.* The ERLIN1-CHUK-CWF19L1 gene cluster influences liver fat deposition and
1302 hepatic inflammation in the NHLBI Family Heart Study. *Atherosclerosis* **228**, 175-80 (2013).
- 1303 14. Kozlitina, J. *et al.* Exome-wide association study identifies a TM6SF2 variant that confers
1304 susceptibility to nonalcoholic fatty liver disease. *Nat Genet* **46**, 352-6 (2014).
- 1305 15. Liu, Y.L. *et al.* TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-
1306 alcoholic fatty liver disease. *Nat Commun* **5**, 4309 (2014).
- 1307 16. Abul-Husn, N.S. *et al.* A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver
1308 Disease. *N Engl J Med* **378**, 1096-1106 (2018).
- 1309 17. Young, K.A. *et al.* Genome-Wide Association Study Identifies Loci for Liver Enzyme
1310 Concentrations in Mexican Americans: The GUARDIAN Consortium. *Obesity (Silver Spring)* **27**,
1311 1331-1337 (2019).
- 1312 18. Namjou, B. *et al.* GWAS and enrichment analyses of non-alcoholic fatty liver disease identify
1313 new trait-associated genes and pathways across eMERGE Network. *BMC Med* **17**, 135 (2019).
- 1314 19. Emdin, C.A. *et al.* A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene
1315 and protection against liver disease. *PLoS Genet* **16**, e1008629 (2020).
- 1316 20. Anstee, Q.M. *et al.* Genome-wide association study of non-alcoholic fatty liver and
1317 steatohepatitis in a histologically characterised cohort(). *J Hepatol* **73**, 505-515 (2020).

- 1318 21. Serper, M. *et al.* Validating a Non-Invasive Non-Alcoholic Fatty Liver Phenotype in the Million
1319 Veteran Program. *PLoS One* (**in press**)(2020).
- 1320 22. Chalasani, N. *et al.* Genome-wide association study identifies variants associated with histologic
1321 features of nonalcoholic Fatty liver disease. *Gastroenterology* **139**, 1567-76, 1576 e1-6 (2010).
- 1322 23. Locke, A.E. *et al.* Genetic studies of body mass index yield new insights for obesity biology.
1323 *Nature* **518**, 197-206 (2015).
- 1324 24. Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and body mass
1325 index in approximately 700000 individuals of European ancestry. *Hum Mol Genet* **27**, 3641-3649
1326 (2018).
- 1327 25. Vujkovic, M. *et al.* Discovery of 318 new risk loci for type 2 diabetes and related vascular
1328 outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet* **52**, 680-
1329 691 (2020).
- 1330 26. Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci associated
1331 with blood pressure traits. *Nat Genet* **50**, 1412-1425 (2018).
- 1332 27. Klarin, D. *et al.* Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million
1333 Veteran Program. *Nat Genet* **50**, 1514-1523 (2018).
- 1334 28. Consortium, G.T. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580-5 (2013).
- 1335 29. Gaziano, J.M. *et al.* Million Veteran Program: A mega-biobank to study genetic influences on
1336 health and disease. *J Clin Epidemiol* **70**, 214-23 (2016).
- 1337 30. Hayward, K.L. *et al.* Detecting non-alcoholic fatty liver disease and risk factors in health
1338 databases: accuracy and limitations of the ICD-10-AM. *BMJ Open Gastroenterol* **8**(2021).
- 1339 31. Husain, N. *et al.* Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration
1340 population: development and validation of an algorithm for NAFLD using automated data.
1341 *Aliment Pharmacol Ther* **40**, 949-54 (2014).
- 1342 32. Fang, H. *et al.* Harmonizing genetic ancestry and self-identified race/ethnicity in genome-wide
1343 association studies. *Am J Hum Gen* **105**, 763-772 (2019).
- 1344 33. de Vries, P.S. *et al.* Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating
1345 Gene-Alcohol Interactions. *Am J Epidemiol* **188**, 1033-1054 (2019).
- 1346 34. Chen, V.L. *et al.* Genome-wide association study of serum liver enzymes implicates diverse
1347 metabolic and liver pathology. *Nat Commun* **12**, 816 (2021).
- 1348 35. Pazoki, R. *et al.* Genetic analysis in European ancestry individuals identifies 517 loci associated
1349 with liver enzymes. *Nat Commun* (**in press**)(2021).
- 1350 36. Stender, S. *et al.* Relationship between genetic variation at PPP1R3B and levels of liver glycogen
1351 and triglyceride. *Hepatology* **67**, 2182-2195 (2018).
- 1352 37. Finucane, H.K. *et al.* Partitioning heritability by functional annotation using genome-wide
1353 association summary statistics. *Nat Genet* **47**, 1228-35 (2015).
- 1354 38. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding from polygenicity in
1355 genome-wide association studies. *Nat Genet* **47**, 291-5 (2015).
- 1356 39. Finucane, H.K. *et al.* Heritability enrichment of specifically expressed genes identifies disease-
1357 relevant tissues and cell types. *Nat Genet* **50**, 621-629 (2018).
- 1358 40. Stephens, C.R. *et al.* The Impact of Education and Age on Metabolic Disorders. *Front Public*
1359 *Health* **8**, 180 (2020).
- 1360 41. Wakefield, J. Bayes factors for genome-wide association studies: comparison with P-values.
1361 *Genet Epidemiol* **33**, 79-86 (2009).
- 1362 42. Adzhubei, I., Jordan, D.M. & Sunyaev, S.R. Predicting functional effect of human missense
1363 mutations using PolyPhen-2. *Curr Protoc Hum Genet* **Chapter 7**, Unit7 20 (2013).
- 1364 43. Ng, M.C. *et al.* Meta-analysis of genome-wide association studies in African Americans provides
1365 insights into the genetic architecture of type 2 diabetes. *PLoS Genet* **10**, e1004517 (2014).

- 1366 44. Caliskan, M. *et al.* Genetic and Epigenetic Fine Mapping of Complex Trait Associated Loci in the
1367 Human Liver. *Am J Hum Genet* **105**, 89-107 (2019).
- 1368 45. Baxter, M. *et al.* Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells
1369 better mimic fetal rather than adult hepatocytes. *J Hepatol* **62**, 581-9 (2015).
- 1370 46. Brancale, J. & Vilarinho, S. A single cell gene expression atlas of 28 human livers. *J Hepatol*
1371 (2021).
- 1372 47. Goldstein, J.A. *et al.* LabWAS: novel findings and study design recommendations from a meta-
1373 analysis of clinical labs in two independent biobanks. *medRxiv*, 2020.04.08.19011478 (2020).
- 1374 48. Sliz, E. *et al.* NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic
1375 effects. *Hum Mol Genet* **27**, 2214-2223 (2018).
- 1376 49. Sticova, E. & Jirsa, M. ABCB4 disease: Many faces of one gene deficiency. *Ann Hepatol* **19**, 126-
1377 133 (2020).
- 1378 50. Gudbjartsson, D.F. *et al.* Large-scale whole-genome sequencing of the Icelandic population. *Nat*
1379 *Genet* **47**, 435-44 (2015).
- 1380 51. Stattermayer, A.F., Halilbasic, E., Wrba, F., Ferenci, P. & Trauner, M. Variants in ABCB4 (MDR3)
1381 across the spectrum of cholestatic liver diseases in adults. *J Hepatol* **73**, 651-663 (2020).
- 1382 52. Dwyer, A. *et al.* Influence of glycogen on liver density: computed tomography from a metabolic
1383 perspective. *J Comput Assist Tomogr* **7**, 70-3 (1983).
- 1384 53. Mehta, M.B. *et al.* Hepatic protein phosphatase 1 regulatory subunit 3B (Ppp1r3b) promotes
1385 hepatic glycogen synthesis and thereby regulates fasting energy homeostasis. *J Biol Chem* **292**,
1386 10444-10454 (2017).
- 1387 54. Brouwers, M., Jacobs, C., Bast, A., Stehouwer, C.D.A. & Schaper, N.C. Modulation of Glucokinase
1388 Regulatory Protein: A Double-Edged Sword? *Trends Mol Med* **21**, 583-594 (2015).
- 1389 55. Wang, L. *et al.* NADP modulates RNA m(6)A methylation and adipogenesis via enhancing FTO
1390 activity. *Nat Chem Biol* **16**, 1394-1402 (2020).
- 1391 56. Wang, C.Y. *et al.* Loss of FTO in adipose tissue decreases Angptl4 translation and alters
1392 triglyceride metabolism. *Sci Signal* **8**, ra127 (2015).
- 1393 57. Chen, Z. *et al.* Functional Screening of Candidate Causal Genes for Insulin Resistance in Human
1394 Preadipocytes and Adipocytes. *Circ Res* **126**, 330-346 (2020).
- 1395 58. Nielsen, J.B. *et al.* Loss-of-function genomic variants highlight potential therapeutic targets for
1396 cardiovascular disease. *Nat Commun* **11**, 6417 (2020).
- 1397 59. Fagerberg, L. *et al.* Analysis of the human tissue-specific expression by genome-wide integration
1398 of transcriptomics and antibody-based proteomics. *Mol Cell Proteomics* **13**, 397-406 (2014).
- 1399 60. Duff, M.O. *et al.* Genome-wide identification of zero nucleotide recursive splicing in *Drosophila*.
1400 *Nature* **521**, 376-9 (2015).
- 1401 61. Jamialahmadi, O. *et al.* Exome-Wide Association Study on Alanine Aminotransferase Identifies
1402 Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease.
1403 *Gastroenterology* **160**, 1634-1646 e7 (2021).
- 1404 62. Hammond, L.E. *et al.* Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have
1405 reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition.
1406 *Mol Cell Biol* **22**, 8204-14 (2002).
- 1407 63. Cuchel, M. *et al.* Inhibition of microsomal triglyceride transfer protein in familial
1408 hypercholesterolemia. *N Engl J Med* **356**, 148-56 (2007).
- 1409 64. Soubeyrand, S., Martinuk, A. & McPherson, R. TRIB1 is a positive regulator of hepatocyte nuclear
1410 factor 4-alpha. *Sci Rep* **7**, 5574 (2017).
- 1411 65. Laudadio, I. *et al.* A feedback loop between the liver-enriched transcription factor network and
1412 miR-122 controls hepatocyte differentiation. *Gastroenterology* **142**, 119-29 (2012).

- 1413 66. Kim, K. *et al.* RORalpha controls hepatic lipid homeostasis via negative regulation of
1414 PPARgamma transcriptional network. *Nat Commun* **8**, 162 (2017).
- 1415 67. Kim, J.Y., Han, Y.H., Nam, M.W., Kim, H.J. & Lee, M.O. RORalpha suppresses interleukin-6-
1416 mediated hepatic acute phase response. *Sci Rep* **9**, 11798 (2019).
- 1417 68. Laatsch, A. *et al.* Low density lipoprotein receptor-related protein 1 dependent endosomal
1418 trapping and recycling of apolipoprotein E. *PLoS One* **7**, e29385 (2012).
- 1419 69. Moon, J.H. *et al.* Upregulation of hepatic LRP1 by rosiglitazone: a possible novel mechanism of
1420 the beneficial effect of thiazolidinediones on atherogenic dyslipidemia. *J Mol Endocrinol* **49**, 165-
1421 74 (2012).
- 1422 70. Skat-Rordam, J., Hojland Ipsen, D., Lykkesfeldt, J. & Tveden-Nyborg, P. A role of peroxisome
1423 proliferator-activated receptor gamma in non-alcoholic fatty liver disease. *Basic Clin Pharmacol*
1424 *Toxicol* **124**, 528-537 (2019).
- 1425 71. Sanyal, A.J. *et al.* Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J*
1426 *Med* **362**, 1675-85 (2010).
- 1427 72. Musso, G., Cassader, M., Paschetta, E. & Gambino, R. Thiazolidinediones and Advanced Liver
1428 Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. *JAMA Intern Med* **177**, 633-640 (2017).
- 1429 73. Ratziu, V. *et al.* Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the
1430 randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT)
1431 Trial. *Gastroenterology* **135**, 100-10 (2008).
- 1432 74. Ratziu, V. *et al.* Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the
1433 fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. *Hepatology* **51**, 445-53
1434 (2010).
- 1435 75. Cusi, K. *et al.* Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis
1436 and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. *Ann Intern Med* **165**, 305-15
1437 (2016).
- 1438 76. Luc, G. *et al.* Distribution of apolipoprotein E between apo B- and non apo B-containing
1439 lipoproteins according to apo E phenotype. *Atherosclerosis* **131**, 257-62 (1997).
- 1440 77. Nakaya, Y., Schaefer, E.J. & Brewer, H.B., Jr. Activation of human post heparin lipoprotein lipase
1441 by apolipoprotein H (beta 2-glycoprotein I). *Biochem Biophys Res Commun* **95**, 1168-72 (1980).
- 1442 78. Lin, K.Y. *et al.* Evidence for inhibition of low density lipoprotein oxidation and cholesterol
1443 accumulation by apolipoprotein H (beta2-glycoprotein I). *Life Sci* **69**, 707-19 (2001).
- 1444 79. Mabile, L. *et al.* Secreted apolipoprotein E reduces macrophage-mediated LDL oxidation in an
1445 isoform-dependent way. *J Cell Biochem* **90**, 766-76 (2003).
- 1446 80. Karavia, E.A., Papachristou, D.J., Kotsikogianni, I., Giopanou, I. & Kypreos, K.E. Deficiency in
1447 apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice.
1448 *FEBS J* **278**, 3119-29 (2011).
- 1449 81. Schierwagen, R. *et al.* Seven weeks of Western diet in apolipoprotein-E-deficient mice induce
1450 metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. *Sci Rep* **5**, 12931
1451 (2015).
- 1452 82. Tilg, H., Adolph, T.E. & Moschen, A.R. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty
1453 Liver Disease: Revisited After a Decade. *Hepatology* **73**, 833-842 (2021).
- 1454 83. Hamada, M., Tsunakawa, Y., Jeon, H., Yadav, M.K. & Takahashi, S. Role of MafB in macrophages.
1455 *Exp Anim* **69**, 1-10 (2020).
- 1456 84. Tran, M.T. *et al.* MafB deficiency accelerates the development of obesity in mice. *FEBS Open Bio*
1457 **6**, 540-7 (2016).
- 1458 85. Hamada, M. *et al.* MafB promotes atherosclerosis by inhibiting foam-cell apoptosis. *Nat*
1459 *Commun* **5**, 3147 (2014).

- 1460 86. Stoffel, W. *et al.* Obesity resistance and deregulation of lipogenesis in Delta6-fatty acid
1461 desaturase (FADS2) deficiency. *EMBO Rep* **15**, 110-20 (2014).
- 1462 87. Ecker, J. *et al.* Induction of fatty acid synthesis is a key requirement for phagocytic
1463 differentiation of human monocytes. *Proc Natl Acad Sci U S A* **107**, 7817-22 (2010).
- 1464 88. Mirea, A.M., Tack, C.J., Chavakis, T., Joosten, L.A.B. & Toonen, E.J.M. IL-1 Family Cytokine
1465 Pathways Underlying NAFLD: Towards New Treatment Strategies. *Trends Mol Med* **24**, 458-471
1466 (2018).
- 1467 89. Hotamisligil, G.S. Inflammation and metabolic disorders. *Nature* **444**, 860-7 (2006).
- 1468 90. Negrin, K.A. *et al.* IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. *PLoS One* **9**,
1469 e107265 (2014).
- 1470 91. Osborn, O. & Olefsky, J.M. The cellular and signaling networks linking the immune system and
1471 metabolism in disease. *Nat Med* **18**, 363-74 (2012).
- 1472 92. Tan, Q. *et al.* The Role of IL-1 Family Members and Kupffer Cells in Liver Regeneration. *Biomed*
1473 *Res Int* **2016**, 6495793 (2016).
- 1474 93. Gieling, R.G., Wallace, K. & Han, Y.P. Interleukin-1 participates in the progression from liver
1475 injury to fibrosis. *Am J Physiol Gastrointest Liver Physiol* **296**, G1324-31 (2009).
- 1476 94. Meier, R.P.H. *et al.* Interleukin-1 Receptor Antagonist Modulates Liver Inflammation and Fibrosis
1477 in Mice in a Model-Dependent Manner. *Int J Mol Sci* **20**(2019).
- 1478 95. Gehrke, N. *et al.* Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1
1479 driven autoinflammation. *J Hepatol* **68**, 986-995 (2018).
- 1480 96. Larsen, C.M. *et al.* Interleukin-1-receptor antagonist in type 2 diabetes mellitus. *N Engl J Med*
1481 **356**, 1517-26 (2007).
- 1482 97. van Asseldonk, E.J. *et al.* One week treatment with the IL-1 receptor antagonist anakinra leads
1483 to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1
1484 diabetes mellitus. *Clin Immunol* **160**, 155-62 (2015).
- 1485 98. Banerjee, A. & Singh, J. Remodeling adipose tissue inflammasome for type 2 diabetes mellitus
1486 treatment: Current perspective and translational strategies. *Bioeng Transl Med* **5**, e10150
1487 (2020).
- 1488 99. Han, Y.H. *et al.* A maresin 1/RORalpha/12-lipoxygenase autoregulatory circuit prevents
1489 inflammation and progression of nonalcoholic steatohepatitis. *J Clin Invest* **129**, 1684-1698
1490 (2019).
- 1491 100. Chai, C. *et al.* Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-
1492 regulation of MicroRNA 122. *Gastroenterology* **159**, 999-1014 e9 (2020).
- 1493 101. West, L.C. & Cresswell, P. Expanding roles for GILT in immunity. *Curr Opin Immunol* **25**, 103-8
1494 (2013).
- 1495 102. Chiang, H.S. & Maric, M. Lysosomal thiol reductase negatively regulates autophagy by altering
1496 glutathione synthesis and oxidation. *Free Radic Biol Med* **51**, 688-99 (2011).
- 1497 103. Chapoval, A.I. *et al.* B7-H3: a costimulatory molecule for T cell activation and IFN-gamma
1498 production. *Nat Immunol* **2**, 269-74 (2001).
- 1499 104. Sun, T.W. *et al.* B7-H3 is expressed in human hepatocellular carcinoma and is associated with
1500 tumor aggressiveness and postoperative recurrence. *Cancer Immunol Immunother* **61**, 2171-82
1501 (2012).
- 1502 105. Kang, F.B. *et al.* B7-H3 promotes aggression and invasion of hepatocellular carcinoma by
1503 targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. *Cancer*
1504 *Cell Int* **15**, 45 (2015).
- 1505 106. Li, L. *et al.* Identification of key genes in nonalcoholic fatty liver disease progression based on
1506 bioinformatics analysis. *Mol Med Rep* **17**, 7708-7720 (2018).

- 1507 107. Baeza-Raja, B. *et al.* Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing
1508 inflammation and fibrosis. *PLoS One* **15**, e0234038 (2020).
- 1509 108. Di Virgilio, F., Dal Ben, D., Sarti, A.C., Giuliani, A.L. & Falzoni, S. The P2X7 Receptor in Infection
1510 and Inflammation. *Immunity* **47**, 15-31 (2017).
- 1511 109. Giuliani, A.L., Sarti, A.C., Falzoni, S. & Di Virgilio, F. The P2X7 Receptor-Interleukin-1 Liaison.
1512 *Front Pharmacol* **8**, 123 (2017).
- 1513 110. Willebrords, J. *et al.* Protective effect of genetic deletion of pannexin1 in experimental mouse
1514 models of acute and chronic liver disease. *Biochim Biophys Acta Mol Basis Dis* **1864**, 819-830
1515 (2018).
- 1516 111. Cooreman, A. *et al.* Connexin and Pannexin (Hemi)Channels: Emerging Targets in the Treatment
1517 of Liver Disease. *Hepatology* **69**, 1317-1323 (2019).
- 1518 112. Cai, B. *et al.* Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. *Cell*
1519 *Metab* **31**, 406-421 e7 (2020).
- 1520 113. Patin, E. *et al.* Genome-wide association study identifies variants associated with progression of
1521 liver fibrosis from HCV infection. *Gastroenterology* **143**, 1244-1252 e12 (2012).
- 1522 114. Wen, Y. & Ju, C. MerTK - A Novel Potential Target to Treat NASH Fibrosis. *Hepatology* (2020).
- 1523 115. Hunter-Zinck, H. *et al.* Genotyping Array Design and Data Quality Control in the Million Veteran
1524 Program. *Am J Hum Genet* **106**, 535-548 (2020).
- 1525 116. Kranzler, H.R. *et al.* Genome-wide association study of alcohol consumption and use disorder in
1526 274,424 individuals from multiple populations. *Nat Commun* **10**, 1499 (2019).
- 1527 117. Justice, A.C. *et al.* AUDIT-C and ICD codes as phenotypes for harmful alcohol use: association
1528 with ADH1B polymorphisms in two US populations. *Addiction* **113**, 2214-2224 (2018).
- 1529 118. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets.
1530 *Gigascience* **4**, 7 (2015).
- 1531 119. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide
1532 association scans. *Bioinformatics* **26**, 2190-1 (2010).
- 1533 120. Hutchinson, A., Watson, H. & Wallace, C. Correcting the coverage of credible sets in Bayesian
1534 genetic fine-mapping. *bioRxiv*, 781062 (2019).
- 1535 121. Haas, M.E. *et al.* Machine learning enables new insights into clinical significance of and genetic
1536 contributions to liver fat accumulation. *medRxiv*, 2020.09.03.20187195 (2020).
- 1537 122. MacLean, M.T. *et al.* Linking abdominal imaging traits to electronic health record phenotypes.
1538 *medRxiv*, 2020.09.08.20190330 (2020).
- 1539 123. Wattacheril, J. *et al.* Genome-Wide Associations Related to Hepatic Histology in Nonalcoholic
1540 Fatty Liver Disease in Hispanic Boys. *J Pediatr* **190**, 100-107 e2 (2017).
- 1541 124. Patton, H.M. *et al.* Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.
1542 *Gastroenterology* **135**, 1961-1971 e2 (2008).
- 1543 125. Kleiner, D.E. *et al.* Design and validation of a histological scoring system for nonalcoholic fatty
1544 liver disease. *Hepatology* **41**, 1313-21 (2005).
- 1545 126. Lin, H.J. *et al.* Home use of a compact, 12lead ECG recording system for newborns. *J*
1546 *Electrocardiol* **53**, 89-94 (2019).
- 1547 127. Weinshilboum, R.M. & Wang, L. Pharmacogenomics: Precision Medicine and Drug Response.
1548 *Mayo Clin Proc* **92**, 1711-1722 (2017).
- 1549 128. Gawrieh, S. *et al.* A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response
1550 to Obeticholic Acid in Patients With NASH. *Hepatol Commun* **3**, 1571-1584 (2019).
- 1551 129. Simon, J.A. *et al.* Phenotypic predictors of response to simvastatin therapy among African-
1552 Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. *Am J Cardiol* **97**,
1553 843-50 (2006).

- 1554 130. Hardy, T. *et al.* The European NAFLD Registry: A real-world longitudinal cohort study of
1555 nonalcoholic fatty liver disease. *Contemp Clin Trials* **98**, 106175 (2020).
- 1556 131. Dewey, F.E. *et al.* Distribution and clinical impact of functional variants in 50,726 whole-exome
1557 sequences from the DiscovEHR study. *Science* **354**(2016).
- 1558 132. Harrison, S.A. *et al.* Selonsertib for patients with bridging fibrosis or compensated cirrhosis due
1559 to NASH: Results from randomized phase III STELLAR trials. *J Hepatol* **73**, 26-39 (2020).
- 1560 133. Roden, D.M. *et al.* Development of a large-scale de-identified DNA biobank to enable
1561 personalized medicine. *Clin Pharmacol Ther* **84**, 362-9 (2008).
- 1562 134. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat*
1563 *Genet* **47**, 1236-41 (2015).
- 1564 135. Consortium, E.P. An integrated encyclopedia of DNA elements in the human genome. *Nature*
1565 **489**, 57-74 (2012).
- 1566 136. Roadmap Epigenomics, C. *et al.* Integrative analysis of 111 reference human epigenomes.
1567 *Nature* **518**, 317-30 (2015).
- 1568 137. Andersson, R. *et al.* An atlas of active enhancers across human cell types and tissues. *Nature*
1569 **507**, 455-461 (2014).
- 1570 138. Fehrmann, R.S. *et al.* Gene expression analysis identifies global gene dosage sensitivity in cancer.
1571 *Nat Genet* **47**, 115-25 (2015).
- 1572 139. Cahoy, J.D. *et al.* A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new
1573 resource for understanding brain development and function. *J Neurosci* **28**, 264-78 (2008).
- 1574 140. Heng, T.S., Painter, M.W. & Immunological Genome Project, C. The Immunological Genome
1575 Project: networks of gene expression in immune cells. *Nat Immunol* **9**, 1091-4 (2008).
- 1576 141. Pers, T.H. *et al.* Biological interpretation of genome-wide association studies using predicted
1577 gene functions. *Nat Commun* **6**, 5890 (2015).
- 1578 142. Schmidt, E.M. *et al.* GREGOR: evaluating global enrichment of trait-associated variants in
1579 epigenomic features using a systematic, data-driven approach. *Bioinformatics* **31**, 2601-6 (2015).
- 1580 143. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122 (2016).
- 1581 144. Genomes Project, C. *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74
1582 (2015).
- 1583 145. Chesi, A. *et al.* Genome-scale Capture C promoter interactions implicate effector genes at GWAS
1584 loci for bone mineral density. *Nat Commun* **10**, 1260 (2019).
- 1585 146. Pashos, E.E. *et al.* Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-like Cells
1586 Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. *Cell Stem Cell* **20**, 558-570
1587 e10 (2017).
- 1588 147. Wingett, S. *et al.* HiCUP: pipeline for mapping and processing Hi-C data. *F1000Res* **4**, 1310
1589 (2015).
- 1590 148. Cairns, J. *et al.* CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C data.
1591 *Genome Biol* **17**, 127 (2016).
- 1592 149. Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased coverage,
1593 supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* **47**,
1594 D607-D613 (2019).
- 1595 150. Gagliano Taliun, S.A. *et al.* Exploring and visualizing large-scale genetic associations by using
1596 PheWeb. *Nat Genet* **52**, 550-552 (2020).
- 1597 151. Denny, J.C. *et al.* PheWAS: demonstrating the feasibility of a phenome-wide scan to discover
1598 gene-disease associations. *Bioinformatics* **26**, 1205-10 (2010).
- 1599 152. Loh, P.R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat*
1600 *Genet* **48**, 1443-1448 (2016).

- 1601 153. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in large-
1602 scale genetic association studies. *Nat Genet* **50**, 1335-1341 (2018).
- 1603 154. Elsworth, B. *et al.* The MRC IEU OpenGWAS data infrastructure. *bioRxiv*, 2020.08.10.244293
1604 (2020).
- 1605 155. Shin, S.Y. *et al.* An atlas of genetic influences on human blood metabolites. *Nat Genet* **46**, 543-
1606 550 (2014).
- 1607 156. Kettunen, J. *et al.* Genome-wide study for circulating metabolites identifies 62 loci and reveals
1608 novel systemic effects of LPA. *Nat Commun* **7**, 11122 (2016).
- 1609 157. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human
1610 phenome. *Elife* **7**(2018).
- 1611 158. Sun, B.B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73-79 (2018).
- 1612 159. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic association
1613 studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).
- 1614 160. Giri, A. *et al.* Trans-ethnic association study of blood pressure determinants in over 750,000
1615 individuals. *Nat Genet* **51**, 51-62 (2019).
- 1616 161. Pulit, S.L. *et al.* Meta-analysis of genome-wide association studies for body fat distribution in
1617 694 649 individuals of European ancestry. *Hum Mol Genet* **28**, 166-174 (2019).
- 1618 162. Teumer, A. *et al.* Genome-wide association meta-analyses and fine-mapping elucidate pathways
1619 influencing albuminuria. *Nat Commun* **10**, 4130 (2019).
- 1620 163. Tin, A. *et al.* Target genes, variants, tissues and transcriptional pathways influencing human
1621 serum urate levels. *Nat Genet* **51**, 1459-1474 (2019).
- 1622 164. Wuttke, M. *et al.* A catalog of genetic loci associated with kidney function from analyses of a
1623 million individuals. *Nat Genet* **51**, 957-972 (2019).
- 1624 165. Astle, W.J. *et al.* The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common
1625 Complex Disease. *Cell* **167**, 1415-1429 e19 (2016).
- 1626 166. Guo, H. *et al.* Integration of disease association and eQTL data using a Bayesian colocalisation
1627 approach highlights six candidate causal genes in immune-mediated diseases. *Hum Mol Genet*
1628 **24**, 3305-13 (2015).
- 1629 167. Lambert, S.A. *et al.* The Human Transcription Factors. *Cell* **175**, 598-599 (2018).
- 1630 168. Garcia-Alonso, L., Holland, C.H., Ibrahim, M.M., Turei, D. & Saez-Rodriguez, J. Benchmark and
1631 integration of resources for the estimation of human transcription factor activities. *Genome Res*
1632 **29**, 1363-1375 (2019).
- 1633 169. Turei, D., Korcsmaros, T. & Saez-Rodriguez, J. OmniPath: guidelines and gateway for literature-
1634 curated signaling pathway resources. *Nat Methods* **13**, 966-967 (2016).
- 1635 170. Ceccarelli, F., Turei, D., Gabor, A. & Saez-Rodriguez, J. Bringing data from curated pathway
1636 resources to Cytoscape with OmniPath. *Bioinformatics* **36**, 2632-2633 (2020).
- 1637